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                                   INTRODUCTION 
 
Coronary heart disease is one of the most common causes of death worldwide 
and is the leading cause of death among men and women. In 1990, ischemic heart 
disease accounted for 6.3 million deaths worldwide. The age standardized incidence 
varies among and within countries. There were about 1.6 million hospital discharges 
for ACS in the US in 2003. About 30% of ACS patients have STEMI. In 
industrialized countries the annual incidence of unstable angina is in the region of 6 
cases per 10,000 people. The incidence of ACS increases with age with a higher 
incidence among men until the age of 70. Women who are 15 years postmenopausal 
are equally likely as men to develop ACS. About 90% of patients with coronary heart 
disease report at least 1 of the major risk factors, including cigarette smoking, 
dyslipidemia, hypertension, diabetes, and abdominal obesity1 . 
 
Patients in India who have acute coronary syndromes have a higher rate of 
STEMI than do patients in developed countries. Since most of these patients were 
poor, less likely to get evidence-based treatments, and had greater 30-day mortality, 
reduction of delays in access to hospital and provision of affordable treatments could 
reduce morbidity and mortality2. 
 
Acute coronary syndrome occurs when an atherosclerotic plaque ruptures, 
leading to thrombus formation within a coronary artery, or coronary thrombosis. 
Patients who develop acute coronary syndrome symptoms such as chest pain and 
diaphoresis require timely evaluation to determine the cause. ACS refers to a range of 
acute myocardial ischaemic states, which include: 
 
• ST-elevation ACS (STE-ACS): patients present with acute chest pain and 
persistent (>20 minutes) ST-segment elevation. Most of these patients will 
develop an ST-elevation MI (STEMI). 
• Non-ST-elevation ACS (NSTE-ACS): patients present with acute chest pain 
but without persistent ST-segment elevation. The ECG shows persistent or 
transient ST-segment depression or T-wave inversion, flat T waves, pseudo-
normalisation of T waves, or no ECG changes at presentation. NSTE-ACS is 
further divided into: 
                                      *Unstable angina: normal troponin levels 
                                      *Non-ST-elevation MI (NSTEMI): a rise in troponin levels. 
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 COMPLICATIONS 
• Acute myocardial infarction. 
• Cardiogenic shock. 
• Ischaemic mitral regurgitation. 
• Supraventricular arrhythmias: rare complication of ischaemia but may 
precipitate ischaemic events. 
• Ventricular arrhythmias: simple and complex premature ventricular 
contractions and nonsustained ventricular tachycardia. 
• Atrioventricular nodal blockade: usually transient in setting of reversible 
ischaemia (treatment is guided by location of block and haemodynamic 
stability)3. 
 
EPIDEMIOLOGY  
The incidence of ACS is clearly associated with increasing age. In 2010, the 
estimated number of incident cases of ACS increased from approximately 167,770 in 
those aged less than 50 years to about 356,000 in those age 80 years or more. On 
average, there are 1.8 cases of incident ACS in men for every one case in women. The 
exception to this is pattern in Italy where there are only 1.1 cases of incident ACS in 
men for every one case of incident ACS  in women.  
 
Datamonitor estimates that in the US and the five major EU markets, 36% of 
cases of ACS are STEMI, 34% are NSTEMI, and 30% are UA. In Japan, Datamonitor 
estimates that 51% of cases of ACS are STEMI, 10% are NSTEMI, and 39% are UA4. 
 
PATHOPHYSIOLOGY  
The coronary arteries become stenosed with age by the deposition of lipid-rich 
atheroma in the sub-endothelial layer. There are a number of factors that have been 
shown to encourage the development of premature coronary disease. These include 
smoking, hypertension, hypercholesterolaemia, diabetes mellitus, obesity and a family 
history. Atherosclerotic plaque formation commences when macrophages are 
attracted to the site of vessel injury. A meshwork of extracellular matrix proteins 
surrounds a lipid core, the latter resulting from the incorporation of bloodstream lipids 
by activated macrophages. Deposits tend to accumulate around bifurcations of the 
arteries and result in reduced blood flow when there is >50% diameter reduction. The 
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medial muscle coat of the coronary arteries is under tonic contraction, mediated by the 
autonomic nervous system, which can affect changes in diameter by constriction or 
dilatation. The imbalance between coronary blood flow and myocardial demand 
produces ischaemia, which is manifest as angina. Thus, although in most cases angina 
occurs in association with increased heart work during physical exercise, it can also 
occur as a result of autonomic changes. For example, angina is classically worse in 
cold weather because changing autonomic tone causes coronary artery constriction. 
When angina only occurs with exercise and it is reproduced by the same degree of 
exercise, this is called chronic stable angina.  
 
The pattern of angina may change with time over years, but can occur more 
abruptly over days. This is usually attributable to the development of a thrombus on 
the surface of an atheromatous plaque within the artery after plaque rupture or 
fissuring. Plaque rupture exposes a mixture of lipid and collagen, both of which 
promote the development of thrombus by platelet adherence and activation, as well as 
activation of the coagulation cascade. There are many factors involved in the 
adherence and activation of platelets ,but the final common pathway of ‘white 
thrombus’ is the activation of glycoprotein (GP) IIb/IIIa receptors, the platelet surface 
membrane receptor for fibrinogen. Fibrinogen cross-links develop between activated 
GP IIb/IIIa receptors, leading to the formation of a platelet thrombus. Thrombus 
development is rapid and so symptom deterioration is sudden.  
 
When the pattern changes so that it occurs more easily than previously, but 
still only on exercise, it is called crescendo angina. When angina occurs at rest this 
means that the myocardium is ischaemic even in the absence of an increase in 
workload and implies critical myocardial perfusion. This constitutes the diagnosis of 
unstable angina (UA). It is not necessary to have a severe artery stenosis in order to 
develop a thrombus. In the majority of cases it is the result of endothelial fissuring on 
the site of a non-significant stenosis5.  
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Processes involved in reduction of blood flow during an acute coronary event. 
 
 
6 
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ETIOLOGY 
Acute coronary syndrome is caused primarily by atherosclerosis. Most cases 
of ACS occur from disruption of a previously nonsevere lesion (an atherosclerotic 
lesion that was previously hemodynamically insignificant yet vulnerable to rupture). 
Elevated demand can produce ACS in the presence of a high-grade fixed coronary 
obstruction, due to increased myocardial oxygen and nutrition requirements, such as 
those resulting from exertion, emotional stress, or physiologic stress (eg, from 
dehydration, blood loss, hypotension, infection, thyrotoxicosis, or surgery). ACS 
without elevation in demand requires a new impairment in supply, typically due to 
thrombosis andor plaque hemorrhage. 
 
The major trigger for coronary thrombosis is considered to be plaque rupture 
caused by the dissolution of the fibrous cap, the dissolution itself being the result of 
the release of metalloproteinases (collagenases) from activated inflammatory cells. 
This event is followed by platelet activation and aggregation, activation of the 
coagulation pathway, and vasoconstriction. This process culminates in coronary 
intraluminal thrombosis and variable degrees of vascular occlusion. Distal 
embolization may occur. The severity and duration of coronary arterial obstruction, 
the volume of myocardium affected, the level of demand on the heart, and the ability 
of the rest of the heart to compensate are major determinants of a patient's clinical 
presentation and outcome. Anemia and hypoxemia can precipitate myocardial 
ischemia in the absence of severe reduction in coronary artery blood flow.  
 
A syndrome consisting of chest pain, ischemic ST-segment and T-wave 
changes, elevated levels of biomarkers of myocyte injury, and transient left 
ventricular apical ballooning (takotsubo syndrome) has been shown to occur in the 
absence of clinical CAD, after emotional or physical stress. The etiology of this 
syndrome is not well understood but is thought to relate to a surge of catechol stress 
hormones and/or high sensitivity to those hormones7.  
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Patients are more likely to develop coronary heart disease if they: 
• smoke cigarettes regularly  
 
• have high blood 
cholesterol level  
• have high blood pressure  
 
• do not get enough 
exercise  
• are diabetic  • have an unhealthy diet 
• are overweight  
 
• drink too much 
alcohol  
 
CLINICAL PRESENTATION  
Most Common Symptoms of ACS include: 
• Chest pain due to the heart muscle not getting enough blood, called angina,      
this discomfort may feel like pressure, burning or tightness. It can occur 
during exercise, periods of emotional stress, after eating a large meal, or even 
while  resting. 
• Pain in other areas; typically the upper arm or jaw. 
• Nausea. 
• Vomiting. 
• Shortness of breath. 
• Sudden, heavy sweating. 
• Light-headedness8. 
DIFFERENTIAL DIAGNOSIS   
• Cardiovascular: ST-segment elevation infarction, acute pericarditis, 
myocarditis, aortic stenosis, aortic dissection, pulmonary embolism. 
• Respiratory: pneumonia, pneumothorax. 
• Gastrointestinal: oesophageal spasm, oesophagitis, gastro-oesophageal reflux, 
acute gastritis, cholecystitis, pancreatitis. 
• Musculoskeletal chest pain. 
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INVESTIGATIONS 
It is essential to exclude a myocardial infarction with ST elevation for which 
immediate thrombolysis is indicated. 
 
12-lead ECG: 
 
¾ To confirm a cardiac basis for presentation and may show pre-existing 
structural or ischaemic heart disease (e.g. left ventricular hypertrophy, Q 
waves). 
¾ A normal or unchanged ECG does not exclude the possibility that chest pain is 
ischaemic in origin. 
¾ Changes that may be seen during episodes of angina include transient ST-             
segment elevations (fixed changes suggest acute infarction). 
¾ In unstable angina (and non-Q wave infarction) the ECG typically shows T-  
wave inversion or ST-segment depression, but the ECG may be normal if 
some  time has elapsed since the last episode of pain. 
 
Cardiac enzymes: 
¾ Within the first 6 hours, the sensitivity of troponins is superior to CK-MB 
for the detection of myocardial infarction. 
¾ Troponin I and T become detectable in serum 3-6 hours after infarction, 
peak at 12-24 hours, and remain raised for up to 14 days.Troponins are 
therefore usually tested 6 and 12 hours after the onset of pain. 
¾ In patients with unstable angina, minor troponin elevations may identify  
patients at risk for subsequent cardiac events and death. Elevated troponin 
levels indicate an increased risk of mortality in both the short-term and 
long-term. Patients with chest pain and elevated troponin levels should 
remain in hospital for further assessment, including an inpatient coronary 
angiogram. 
 
Full blood count(FBC): 
FBC may be useful in patients with suspected anaemia and as a baseline in 
view of use of anticoagulants; blood glucose, renal function and electrolytes.  
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Blood glucose: 
 
Hyperglycaemia is common in people admitted to hospital with ACS. 
Hyperglycaemia at the time of admission with ACS is a powerful predictor of poorer 
survival and increased risk of complications while in hospital, regardless of whether 
or not the patient has diabetes. 
 
Echocardiography: 
Echocardiography often demonstrates wall motion abnormalities due to 
ischaemia. May be useful in identifying precipitants for ischaemia, e.g. ventricular 
hypertrophy and valvular disease. 
 
Chest X-Ray(CXR): 
 
CXR may show complications of ischaemia, e.g. pulmonary oedema, or 
explore alternative diagnoses, e.g. pneumothorax, aortic aneurysm. 
 
Cardiac Magnetic Resonance (CMR) Imaging: 
 
       Cardiac magnetic resonance imaging can be useful for the assessment of                        
function and perfusion, and the detection of scar tissue. CMR can also be useful to 
exclude or detect ACS, assess myocardial viability and to detect myocarditis. 
 
Coronary Angiography: 
 
Coronary angiography provides information on the presence and severity of 
coronary artery disease and therefore remains the gold standard9. 
 
NON PHARMACOLOGICAL INTERVENTION 
On admission, patients had poor knowledge of cardiovascular risk factors and 
recommended lifestyle modifications, especially concerning diabetes, hypertension, 
and diet. After completing the rehabilitation programme, significantly higher 
percentage of patients gave correct answers to questions concerning diabetes and 
cholesterol-rich diet as cardiovascular risk factors, and substitution of vegetable fat 
for animal fat as a lifestyle modification, and significantly higher proportion of 
patients gave the correct value for elevated systolic blood pressure. 
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Steps to prevent acute coronary syndrome or to prevent acute coronary syndrome are 
quitting smoking, have exercise most days of the week for at least 30 minutes each 
time, taking a healthy diet, regular check up of blood pressure and cholesterol levels, 
maintain a healthy weight, managing stress 10. 
 
DRUG THERAPY 
The treatment of patients with non-ST-segment elevation ACS is directed to 
alleviate pain and anxiety, prevent recurrences of ischaemia and prevent or limit 
progression to acute myocardial infarction. Treatment includes antithrombotic 
treatment, as well as coronary angiography followed by revascularisation if 
appropriate. 
 
Immediate management of a suspected ACS 
• Arrange urgent hospital admission  
• Resuscitation as required. 
• Pain relief: glyceryl trinitrate (GTN) and/or an intravenous opioid (use an 
antiemetic with opioids). 
• Single loading dose of 300 mg aspirin unless the person is allergic. 
• A resting 12-lead ECG - but don't delay transfer to hospital. 
• Assess oxygen saturation, using pulse oximetry before hospital admission if 
possible. Give oxygen if oxygen saturation (SpO2) is less than 94% with no 
risk of hypercapnic respiratory failure; aim for SpO2 of 94-98% (aim for 88-
92% for people with chronic obstructive pulmonary disease). 
 
    Anti platelet and anticoagulant therapy 
           Aspirin: 
           Single 300-mg loading dose to all patients, unless contra-indicated, and     
continue indefinitely. Consider clopidogrel monotherapy for patients with aspirin 
hypersensitivity. 
 
     Clopidogrel: 
 Offer a 300-mg loading dose to patients with a predicted 6-month 
mortality of more than 1.5% and no contra-indications (such as increased 
bleeding risk). 
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 Offer a 300-mg loading dose to all patients with no contra-indications 
who may undergo PCI within 24 hours of admission. 
 Continue standard dose for 12 months. 
 Consider stopping clopidogrel 5 days before CABG in patients with low 
risk. For patients at intermediate or higher risk, whether to continue 
clopidogrel before CABG depends on the balance of ischaemic and 
bleeding risk. 
 
Prasugrel 
Prasugrel in combination with aspirin is recommended as an option for preventing 
atherothrombotic events in people with acute coronary syndromes having 
percutaneous coronary intervention, only when:  
 immediate primary percutaneous coronary intervention for ST-segment-
elevation myocardial infarction is necessary; or 
 stent thrombosis has occurred during clopidogrel treatment; or the patient has 
diabetes mellitus 
 
    Ticagrelor 
Ticagrelor in combination with low-dose aspirin is recommended for up to 12 
months as a treatment option in adults with acute coronary syndromes (ACS) with: 
STEMI that cardiologists intend to treat with primary percutaneous coronary 
intervention (PCI); or NSTEMI; or admitted to hospital with unstable angina. 
 
    Glycoprotein IIb/IIIa inhibitors: 
 Consider eptifibatide or tirofiban for patients at intermediate or higher risk if   
angiography is scheduled within 96 hours of admission. 
 Consider abciximab as an adjunct to PCI for patients at intermediate or higher 
risk who are not already receiving a glycoprotein inhibitor (GPI). 
 
Antithrombin therapy : 
Anticoagulants  are used in the treatment of NSTE-ACS to inhibit thrombin 
generation and/or activity, thereby reducing thrombus-related events.  
 
 Offer fondaparinux to patients without a high bleeding risk unless angiography 
is planned within 24 hours of admission.  
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 Offer unfractionated heparin as an alternative to fondaparinux if angiography 
is likely within 24 hours of admission 
 Carefully consider the choice and dose of antithrombin in patients with a high 
bleeding risk. 
 Consider unfractionated heparin, with dose adjusted to clotting function, for 
patients with creatinine above 265 μmol/L. 
 Offer systemic unfractionated heparin (50-100 units/kg) in the cardiac catheter 
laboratory to patients on fondaparinux who are undergoing PCI. 
 As an alternative to the combination of a heparin plus a GPI, consider 
bivalirudin for patients who are at intermediate or higher risk, and are not 
already receiving a GPI or fondaparinux, and are scheduled for angiography 
within 24 hours of admission. 
 As an alternative to the combination of a heparin plus a GPI, consider 
bivalirudin for patients undergoing PCI who are at intermediate or higher risk 
and are not already on a GPI or fondaparinux. 
 
Revascularisation: 
 Offer coronary angiography (with follow-on PCI if indicated) within 96 hours 
of first admission to hospital to patients who have an intermediate or higher risk 
of adverse cardiovascular events (predicted 6-month mortality above 3%) if 
they have no contra-indications to angiography such as active bleeding or 
comorbidity) Perform angiography as soon as possible for patients who are 
clinically unstable or at high ischaemic risk. 
 When the role of revascularisation or the revascularisation strategy is unclear, 
resolve this by discussion involving an interventional cardiologist, cardiac 
surgeon and other healthcare professionals relevant to the needs of the patient. 
Discuss the choice of the revascularisation strategy with the patient. 
 The proportion of patients with NSTE-ACS undergoing coronary artery bypass 
surgery during initial hospitalisation is about 10%. The benefit from bypass 
surgery is greatest when patients can be operated on after several days of 
medical stabilisation depending on the individual risk. 
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Other treatments: 
 
 Nitrates (sublingual, oral or intravenous): for ongoing pain whilst waiting for 
more definitive procedures, and may overcome superimposed coronary artery 
spasm. 
 Beta-blockers improve outcome and can reduce the severity and frequency of 
attacks. 
 Calcium antagonists (e.g. diltiazem, verapamil) are used for patients who 
cannot tolerate a beta-blocker, or are used in addition to a beta-blocker. 
Verapamil should not be combined with a beta-blocker. 
 Angiotensin-converting enzyme (ACE) inhibitors reduce mortality and 
should be started when the patient is an inpatient unless contra-indicated. 
 
Hyperglycaemia:  
 
 Hyperglycaemia in patients admitted to hospital for an ACS should be managed 
by keeping blood glucose levels below 11.0 mmol/L while avoiding 
hypoglycaemia. A dose-adjusted insulin infusion with regular monitoring of 
blood glucose levels should be considered. 
 All patients with hyperglycaemia after ACS and without known diabetes should 
be tested for HbA1c levels before discharge and fasting blood glucose levels no 
earlier than 4 days after the onset of ACS. 
 
After stabilisation, secondary risk reduction measures should be implemented. 
These measures include stopping smoking, continued aspirin therapy, management of 
hypertension if present, statins, ACE inhibitors and beta-blockers.If a patient was 
stabilised with medical treatment then it is likely they will undergo treadmill exercise 
testing11. 
 
Further management 
• To detect and quantify inducible ischaemia, consider ischaemia testing before 
discharge for patients whose condition has been managed conservatively and 
who have not had coronary angiography. 
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• Assess left ventricular function in all patients who have had a myocardial 
infarction and consider assessing left ventricular function in all patients with 
unstable angina. 
• Cardiac rehabilitation: rehabilitation and discharge planning. 
• Secondary prevention: management of cardiovascular risk factors with 
lifestyle changes and drug therapy as indicated12. 
 
HYPERTENSION 
High blood pressure, termed "hypertension," is a condition that afflicts almost 
1 billion people worldwide and is a leading cause of morbidity and mortality. More 
than 20% of Americans are hypertensive, and one-third of these Americans are not 
even aware they are hypertensive. Therefore, this disease is sometimes called the 
"silent killer." This disease is usually asymptomatic until the damaging effects of 
hypertension such as stroke, myocardial infarction, renal dysfunction, visual 
problems, etc are observed. Hypertension is a major risk factor for coronary artery 
disease and "heart attacks," which may require coronary artery bypass surgery13. 
 
Normal blood pressure is defined as an average systolic blood pressure of 120 
mm Hg and an average diastolic pressure of 80 mm Hg. Systolic pressure measures 
the pressure in arteries when your heart beats. Diastolic pressure measures the 
pressure between beats. Hypertension is defined as an average systolic blood pressure 
above 140 mm Hg, a diastolic blood pressure above 90 mm Hg, or both14. 
 
Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High 
blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of 
the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over 
the body)15. 
 
The two major types are: 
• Primary or essential hypertension, that has no known cause, is diagnosed in 
the majority of people. 
• Secondary hypertension is often caused by reversible factors, and is 
sometimes curable. 
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The other types include: 
• Malignant Hypertension. 
• Isolated Systolic Hypertension 
• White Coat Hypertension 
• Resistant Hypertension 
 
Primary Hypertension: 
This type is also called essential hypertension, and it is by far the most common type 
of hypertension, and is diagnosed in about 95% of cases. Essential hypertension has 
no obvious or yet identifiable cause. 
 
Secondary Hypertension: 
This may be caused by: 
• Kidney damage or impaired function (This accounts for most secondary forms 
of hypertension.) 
• Tumours or overactivity of the adrenal gland 
• Thyroid dysfunction 
• Coarctation of the aorta 
• Pregnancy-related conditions 
• Sleep Apnea Syndrome 
• Medication, recreational drugs, drinks & food 
 
Malignant Hypertension 
This, the most severe form of hypertension, is severe and progressive. It 
rapidly leads to organ damage. Unless properly treated, it is fatal within five years for 
the majority of patients.  Death usually comes from heart failure, kidney damage or 
brain haemorrhage. However, aggressive treatment can reverse the condition, and 
prevent its’ complications. Malignant hypertension is becoming relatively rare, and is 
not caused by cancer or malignancy. 
Isolated Systolic Hypertension 
In this case the systolic blood pressure  is consistently above 160 mm Hg and 
the diastolic below 90 mm Hg. This may occur in older people, and results from the 
age-related stiffening of the arteries. The loss of elasticity in arteries, like the aorta, is 
mostly due to arteriosclerosis. The Western lifestyle and diet is believed to be the root 
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cause. Latest studies confirm the importance of treating ISH, as it significantly 
reduces the incidence of stroke and heart disease. Treatment starts with lifestyle 
modification, and if needed, added drugs. 
 
White coat hypertension 
Also called anxiety-induced hypertension, it means blood pressure is only high 
when tested by a health professional.  If confirmed, with repeat readings outside of the 
clinical setting, or a 24-hour monitoring device, it does not need to be treated.  
However, regular follow-up is recommended to ensure that persistent hypertension 
has not developed. 
 
Lifestyle changes like more exercise, less salt and alcohol, no nicotine and 
weight loss, would be wise.  A low fat, high fibre diet, with increased fruit and 
vegetable intake, will be beneficial. 
 
Resistant Hypertension 
If blood pressure cannot be reduced to below 140/90 mmHg, despite a triple-
drug regime, resistant hypertension is considered16.  
 
COMPLICATIONS  
• Artery Damage 
• Blindness 
• Kidney Failure 
• Metabolic Syndrome 
• Memory Loss 
• Aneurysm 
• Stroke 
 
EPIDEMIOLOGY 
In many countries, 50% of the population older than 60 years has 
hypertension. Overall, approximately 20% of the world’s adults are estimated to have 
hypertension. The 20% prevalence is for hypertension defined as BP in excess of 
140/90 mm Hg. The prevalence dramatically increases in patients older than 60 years. 
However, approximately 30% of adults are still unaware of their hypertension; up to 
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40% of people with hypertension are not receiving treatment; and, of those treated, up 
to 67% do not have their blood pressure (BP) controlled to less than 140/90 mm Hg17. 
Cardiovascular diseases caused 2.3 million deaths in India in the year 1990; this is 
projected to double by the year 2020. Hypertension is directly responsible for 57% of 
all stroke deaths and 24% of all coronary heart disease deaths in India. Indian urban 
population studies in the mid-1950s used older WHO guidelines for diagnosis (BP > 
or =160 and/or 95 mmHg) and reported hypertension prevalence of 1.2-4.0%. 
Subsequent studies report steadily increasing prevalence from 5% in 1960s to 12-15% 
in 1990s. Hypertension prevalence is lower in the rural Indian population, although 
there has been a steady increase over time here as well. . Pooling of epidemiological 
studies shows that hypertension is present in 25% urban and 10% rural subjects in 
India. At an underestimate, there are 31.5 million hypertensives in rural and 34 
million in urban populations17. 
 
PATHOPHYSIOLOGY 
The pathogenesis of essential hypertension is multifactorial and highly 
complex. Multiple factors modulate the blood pressure (BP) for adequate tissue 
perfusion and include humoral mediators, vascular reactivity, circulating blood 
volume, vascular caliber, blood viscosity, cardiac output, blood vessel elasticity, and 
neural stimulation. A possible pathogenesis of essential hypertension has been 
proposed in which multiple factors, including genetic predisposition, excess dietary 
salt intake, and adrenergic tone, may interact to produce hypertension. Although 
genetics appears to contribute to essential hypertension, the exact mechanism has not 
been established.  
 
The natural history of essential hypertension evolves from occasional to 
established hypertension. After a long invariable asymptomatic period, persistent 
hypertension develops into complicated hypertension, in which target organ damage 
to the aorta and small arteries, heart, kidneys, retina, and central nervous system is 
evident. The progression begins with prehypertension in persons aged 10-30 years (by 
increased cardiac output) to early hypertension in persons aged 20-40 years (in which 
increased peripheral resistance is prominent) to established hypertension in persons 
aged 30-50 years, and, finally, to complicated hypertension in persons aged 40-60 
years. One mechanism of hypertension has been described as high-output 
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hypertension. High-output hypertension results from decreased peripheral vascular 
resistance and concomitant cardiac stimulation by adrenergic hyperactivity and 
altered calcium homeostasis. A second mechanism manifests with normal or reduced 
cardiac output and elevated systemic vascular resistance due to increased 
vasoreactivity. Another mechanism is increased salt and water reabsorption  by the 
kidney, which increases circulating blood volume18.  
 
ETIOLOGY  
Environmental and genetic causes 
Hypertension develops secondary to environmental factors, as well as to 
multiple genes, whose inheritance appears to be complex. Very rare secondary causes 
are related to single genes and include Liddle syndrome, glucocorticoid-remediable 
hyperaldosteronism, 11 beta-hydroxylase and 17 alpha-hydroxylase deficiencies, the 
syndrome of apparent mineralocorticoid excess, and pseudohypoaldosteronism type 
II. Primary or essential hypertension accounts for 90-95% of adult cases, and a small 
percentage of patients (2-10%) have a secondary cause. 
 
Causes of secondary hypertension 
• Polycystic kidney disease 
• Chronic kidney disease 
• Urinary tract obstruction 
• Renin-producing tumor 
• Liddle syndrome 
 Vascular causes  
   
• Coarctation of aorta 
• Vasculitis 
• Collagen-vascular disease 
Endogenous hormonal causes include the following: 
• Primary hyperaldosteronism 
• Cushing syndrome 
• Pheochromocytoma 
• Congenital adrenal hyperplasia 
Neurogenic causes include the following: 
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• Brain tumor 
• Bulbar poliomyelitis 
• Intracranial hypertension 
Other causes include the following: 
• Hyperthyroidism and hypothyroidism 
• Hypercalcemia 
• Hyperparathyroidism 
• Acromegaly 
• Obstructive sleep apnea 
• Pregnancy-induced hypertension19. 
 
CLINICAL PRESENTATION 
• Chronic headaches 
• Dizziness or Vertigo 
• Blurry or double vision.  
• Drowsiness  
• Nausea  
• Shortness of breath. Usually when this occurs people start to get a little 
concerned. Often by this time though the blood pressure has probably reached 
high enough levels to be dangerous as this is one of the last symptoms of 
hypertension you'll experience.  
• Heart palpitations  
• Fatigue - general tiredness  
• A flushed face  
• Nosebleeds  
• A strong need to urinate often especially during the night 
• Tinnitus20. 
 
DIAGNOSIS 
The most precise way to measure blood pressure is to place a small tube or 
catheter into an artery and directly measure the pressures. Usually, a much simpler 
method is employed. The health care provider places a blood pressure cuff around the 
upper arm and inflates the cuff with air. As the cuff becomes filled with air, the 
pressure in the cuff increases, eventually cutting off the flow of blood through the 
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arteries in the arm. The health care provider slowly lets air leak out of the blood 
pressure cuff, causing the pressure in the cuff to gradually decrease. When the 
pressure in the cuff falls below the systolic blood pressure in the arteries, the provider 
begins to hear a characteristic thumping sound as blood starts to flow again in the 
arm. The blood pressure cuff continues to deflate, and when the pressure in the cuff 
falls below the diastolic blood pressure in the arteries, the characteristic thumping 
sound disappears. By listening for the beginning and termination of this sound and 
simultaneously watching the pressure gauge in the cuff when these events occur, the 
health care provider determines the systolic and diastolic blood pressure. 
 
If the blood pressure is not measured correctly, the readings obtained may be 
artificially high. Several steps ensure that the measured blood pressure truly 
represents the patient's blood pressure: 
 
1. Patients should sit with their arms supported at heart level. 
2. Patients should not smoke or ingest caffeine for 30 minutes prior to blood 
pressure measurement. 
3. Patients should sit down for at least 5 minutes before blood pressure is 
measured. 
4. The bladder of the blood pressure cuff should encircle at least 80% of the arm. 
A large cuff should be used for patients with thick arms. 
5. Two or more readings should be taken at least 2 minutes apart. 
 
Evaluation of patients with high blood pressure consists primarily of the 
following: 
• Focused history to collect important data including symptoms like chest pain 
• Family history of high blood pressure 
• Medical history of co-existing conditions like diabetes 
• Physical examination 
• Blood tests 
• Electrocardiogram 
• Echocardiogram or ultrasound of the heart21. 
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LIFE STYLE MODIFICATION 
Lifestyle modifications that effectively lower blood pressure are increased 
physical activity, weight loss, limited alcohol consumption, reduced sodium intake 
and the dietary Approaches to Stop hypertension diet. Lifestyle modification is 
recommended as initial therapy in stage 1 hypertension before initiation of drug 
therapy and as an adjunct to medication in persons already on drug therapy. In pre-
hypertensives, it can reduce the incidence of hypertension and lower end-organ 
damage. It is emphasized that simple advice from physicians can have a positive 
influence on patients' motivation to make lifestyle changes22. 
 
DRUG THERAPY 
General Therapeutic Principles 
 In most hypertensives there is little to be gained from the pursuit of rapid 
blood pressure control. The most important therapeutic goal for the vast majority is to 
prescribe a combination of appropriate lifestyle modifications (weight loss, salt and 
alcohol restriction, and increased physical activity) plus the lowest doses of drugs that 
allow blood pressure normalization over the long term. The erroneous clinical 
perception that diastolic blood pressure is the predominant pressure mediator of 
clinical risk contributes to physician hesitancy to intensify treatment to normalize 
systolic blood pressure once diastolic blood pressure has been lowered to less than 90 
mm Hg. Many antihypertensive medications have dose-related side effects. Drug 
acquisition costs also usually increase at higher dose levels. In certain instances, cost 
is a major barrier to patient compliance with prescribed drug therapies. Drug 
acquisition costs are but one consideration, albeit an important one, in embarking on a 
hypertension disease management strategy23. 
 
Diuretics 
Diuretics, commonly called “water pills,” are the oldest and least expensive 
class of drugs used to treat hypertension .They help the kidneys eliminate sodium and 
water from the body. This process decreases blood volume, so heart has less to pump 
with each beat, which in turn lowers blood pressure. Common side effects of these 
drugs include frequent urination, light headedness, fatigue, diarrhea or constipation, 
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muscle cramps and potassium depletion, so need potassium supplements when taking 
these drugs.               
 
Thiazide diuretics-chlorothiazide,hydrochlorothiazide,chlorthalidone. 
Loop diuretic-Furosemide. 
Potassium sparing diuretic-Spiranolactone24. 
 
Beta blockers 
These drugs are effective in hypertension because they decrease the heart rate and 
cardiac output. Even after continued use of β-blockers, cardiac output remains lower 
and systemic vascular resistance higher with agents that do not have intrinsic 
sympathomimetic or α-blocking activity. The β-blockers also decrease renin release 
and are more efficacious in populations with elevated plasma renin activity, such as 
younger white patients. The side effects of all β-blockers include inducing or 
exacerbating bronchospasm in predisposed patients (eg, those with asthma and some 
patients with chronic obstructive pulmonary disease [COPD]),sinus node dysfunction 
and atrioventricular (AV) conduction depression ,precipitating or worsening clinically 
important left ventricular failure, nasal congestion, Raynaud's phenomenon,and 
central nervous system symptoms with nightmares, excitement, depression, and 
confusion, fatigue, lethargy, and impotence may occur.  
Eg-atenolol,propranalol,labetalol. 
 
ACE inhibitors 
ACE inhibitors are being increasingly used as the initial medication in mild to 
moderate hypertension. Their primary mode of action is inhibition of the renin-
angiotensin-aldosterone system, but they also inhibit bradykinin degradation, 
stimulate the synthesis of vasodilating prostaglandins and, sometimes, reduce 
sympathetic nervous system activity.Side effects are chronic dry 
cough,hperkalemia,dizziness,skin rashes,angioodema. 
Eg-Ramipril,captopril,enlapril. 
 
Angiotensin II receptor blockers 
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The final active messenger of the renin-angiotensin pathway is angiotensin II. 
Angiotensin II binds to AT1 receptors to cause vasoconstriction and fluid retention, 
both of which lead to an increase in blood pressure. The angiotensin II receptor 
blockers lower blood pressure by blocking the AT1 receptors. The ARBs do not cause 
cough and are only infrequently associated with skin rashes.Common side effects are 
renal failure,hyperkalemia, hepatotoxicity, angioneurotic edema, and neuropsychiatric 
symptoms. 
Eg-Losartan,telmisartan,valsartan. 
 
Calcium channel blockers 
 
Calcium channel antagonists block inward movement of calcium by binding to 
the L-type calcium channels in the heart and in smooth muscle of the pericardial 
vasculature.calcium channel blockers dilate coronary arteries and peripheral 
arterioles,but not veins. 
 
The most common side effects of calcium channel blockers are headache, 
peripheral edema bradycardia, and constipation. 
Eg-verapamil,diltiazem. 
 
Alpha-adrenoceptor antagonists 
They block postsynaptic α-receptors, relax smooth muscle, and reduce blood 
pressure by lowering peripheral vascular resistance. These agents are effective as 
single-drug therapy in some individuals, but tachyphylaxis may appear during long-
term therapy.Common side effects are dizziness,fainting,low blood pressure,sudden 
blood pressure changes when standing after sitting. 
Eg-Prazosin, terazosin, and doxazosin. 
 
Drugs with central sympatholytic action 
They lower blood pressure by stimulating α-adrenergic receptors in the central 
nervous system, thus reducing efferent peripheral sympathetic outflow. These agents 
are effective as single therapy in some patients, but they are usually used as second- 
or third-line agents because of the high frequency of drug intolerance, including 
sedation, fatigue, dry mouth, postural hypotension, and impotence. 
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Eg-Methyldopa, clonidine, guanabenz, and guanfacine25. 
 
Arteriolar dilators 
They relax vascular smooth muscle and produce peripheral vasodilation. They 
are usually given in combination with diuretics and β-blockers in resistant patients. 
Common side effects are headache, palpitations,  fluid retention, hirsutism, lupus-like 
syndrome. 
Eg-Hydralazine and minoxidil 26. 
 
HIGH SENSITIVITY C-REACTIVE PROTEIN: 
  hs-CRP has emerged as a strong, robust and independent risk factor for CVD 
that appears to have significant clinical utility. It is a circulating acute phase reactant 
named initially for its capacity to bind to the c-polysaccharide of Streptococcus 
pneumoniae, and is synthesized primarily by the liver in response to IL-6 and IL-1 . 
As a risk assessment tool, it has several good points. It is very stable  with very little 
difference in values between fresh or frozen plasma and has a long half-life of up to 
20 h.It normally circulates at very low levels, but acute inflammatory processes 
induce marked hepatic synthesis of hs-CRP, which can induce a 100-fold serum 
increase. 
 
Evidence has shown that, even in apparently healthy subjects, there is good 
and consistent significant relationship between baseline hs-CRP levels and risk of 
future cardiovascular events such as stroke, peripheral vascular disease, sudden 
cardiac death and myocardial infarction. In those with existing CVD, it has been 
shown to predict future cardiovascular events27. Laboratory and experimental 
evidence indicate that atherosclerosis, in addition to being a disease of lipid 
accumulation also represents a chronic inflammatory process. Thus, researchers have 
hypothesized that inflammatory markers such as high-sensitivity c-reactive protein 
(hs-CRP) may provide an adjunctive method for global assessment of cardiovascular 
risk. In support of this hypothesis, several large-scale prospective epidemiological 
studies have shown that plasma levels of hs-CRP are a strong independent predictor 
of risk of future myocardial infarction, stroke, peripheral arterial disease, and vascular 
death among individuals without known cardiovascular disease. In addition, among 
patients with acute coronary ischemia, stable angina pectoris, and a history of 
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myocardial infarction, levels of hS-CRP have been associated with increased vascular 
event rates.  
Based in part on these data, high-sensitivity assays for CRP have become available in 
standard clinical laboratories. However, clinical application of hs-CRP testing will 
depend not only on demonstration of independent predictive value, but also on 
demonstration that addition of hs-CRP testing to traditional screening methods 
improves cardiovascular risk prediction. Furthermore, application of hs-CRP as a tool 
to assist in global risk assessment requires knowledge of population distribution of hs-
CRP, clinical characteristics of hs-CRP evaluation, and magnitude of risk of future 
coronary events that can be expected at each level of hs-CRP28.  
 
High Sensitivity C-Reactive Protein (hs-CRP) Assay 
The high-sensitivity C-reactive protein (hs-CRP) assay is a quantitative 
analysis test of very low levels of C-reactive protein (CRP) in the blood. Following a 
systematic review of the association between inflammatory markers and coronary 
heart disease and stroke, the American Heart Association (AHA) and Centers for 
Disease Control and Prevention (CDC) developed a scientific statement that 
recommends hs-CRP as a more sensitive assay for the prediction of vascular disease, 
compared to traditional assays for circulating C-reactive protein levels29 . 
 
The AHA/CDC Scientific Statement Summary 
• hs-CRP is a global indicator of future vascular events in adults without any 
previous history of cardiovascular disease. 
• hs-CRP enhances risk assessment and therapeutic outcomes in primary CVD 
prevention.  
• hs-CRP acts as an independent marker for evaluating the possibility of 
recurrent cardiac events such as myocardial infarction or restenosis, after 
percutaneous coronary intervention. 
 
Clinical Applications 
hs-CRP in Atherosclerosis and Plaque Instability/Inflammation 
  With the recognition of the crucial link between arterial damage, inflammatory 
processes, and coronary atherosclerosis, hs-CRP estimation has assumed a vital role 
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in cardiac risk assessment. C-reactive protein is an important pathogenic factor for 
atherosclerosis and induces several reactions involved in atherothrombogenesis:  
• Activates complement and attacks monocytes.  
• Incites endothelial dysfunction.  
• Augments a procoagulant state.  
• Contributes to plaque instability/rupture. 
  
hs-CRP in Risk Stratification and Risk Assessment  
hs-CRP levels help in cardiac risk stratification and assessment, and it are a 
key prognostic factor in conditions such as: 
• Acute coronary syndrome.  
• Stroke.  
• Peripheral artery disease.  
• Post-MI complications such as cardiac failure. 
 
Risk Stratification 
  hs-CRP is used to determine the probability of recurrence of cardiac events in 
patients with stable coronary heart disease and ACS.  
 
Risk Assessment 
The hs-CRP assay has been recommended in patients with intermediate risk of 
coronary heart disease in order to determine the need for further evaluation and 
therapy30.  
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                                      DRUG PROFILE 
                                           RAMIPRIL 
 
BRAND NAME: Cardace, Macpril ,Ramace 
 
CHEMICAL NAME: [2S - [1[R*(R*)],2α,3aβ,6aβ]] - 1 - [2 - [[1 - (Ethoxycarbonyl) 
- 3 - phenylpropyl]amino] - 1 - oxopropy l]octahydrocylopenta[b]pyrrole-2-carboxylic 
acid. 
CHEMICAL FORMULA: C21H28N2O51 
 
STRUCTURAL FORMULA: 
                                         
 
 
DESCRIPTION:  
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) 
inhibitor class of medications. It is metabolized to ramiprilat in the liver and  to a 
lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the 
enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). 
ATII regulates blood pressure and is a key component of the renin-angiotensin-
aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, 
congestive heart failure, nephropathy, and to reduce the rate of death, myocardial 
infarction and stroke in individuals at high risk of cardiovascular events31. 
 
DOSAGE FORM: Tablet  
MECHANISM OF ACTION: 
There are two isoforms of ACE: the somatic isoform, which exists as a 
glycoprotein comprised of a single polypeptide chain of 1277; and the testicular 
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isoform, which has a lower molecular mass and is thought to play a role in sperm 
maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two 
functionally active domains, N and C, which arise from tandem gene duplication. 
Although the two domains have high sequence similarity, they play distinct 
physiological roles. The C-domain is predominantly involved in blood pressure 
regulation while the N-domain plays a role in hematopoietic stem cell differentiation 
and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but 
have much greater affinity for and inhibitory activity against the C-domain. 
Ramiprilat, the principle active metabolite of ramipril, competes with ATI for binding 
to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII 
levels in the body decreases blood pressure by inhibiting the pressor effects of ATII 
.Ramipril also causes an increase in plasma renin activity likely due to a loss of 
feedback inhibition mediated by ATII on the release of renin and/or stimulation of 
reflex mechanisms via baroreceptors32. 
 
CLINICAL PHARMACOLOGY 
 PHARMACODYNAMICS: 
It is an inactive prodrug that is converted to ramiprilat in the liver, the main 
site of activation, and kidneys. Ramiprilat confers blood pressure lowing effects by 
antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for 
regulating hemodynamics, water and electrolyte balance. During sympathetic 
stimulation or when renal blood pressure or blood flow is reduced, renin is released 
from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood 
stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently 
cleaved to ATII by ACE. ATII increases blood pressure using a number of 
mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. 
Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of 
nephrons where it increases sodium and water reabsorption by increasing the number 
of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII 
stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) 
from the posterior pituitary gland. ADH stimulates further water reabsorption from 
the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the 
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DCT and collecting tubules. Third, ATII increases blood pressure through direct 
arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth 
muscle cells leads to a cascade of events resulting in myocyte contraction and 
vasoconstriction. In addition to these major effects, ATII induces the thirst response 
via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion 
of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also 
known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a 
vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and 
may sustain the effects of ramiprilat by causing increased vasodilation and decreased 
blood pressure. 
 
PHARMACOKINETICS: 
Absorption 
Bioavailability 
Following oral administration, peak plasma concentrations of ramipril usually 
attained within 1 hour. Peak plasma concentrations of ramiprilat attained within 2–4 
hours after oral dose. About ≥50–60% of an oral dose is absorbed. 
Following multiple oral doses (≥2 mg), >90% inhibition of plasma ACE 
activity achieved 4 hours after dosing. 
Following multiple oral doses (≥2 mg), inhibition of >80% of plasma ACE 
activity persists for about 24 hours. 
Food decreases rate but not extent of absorption. 
 
Distribution 
Distributes into a large peripheral compartment. Crosses the placenta. 
Undetectable in human milk following single oral dose; not known whether 
distributed into milk following multiple doses. 
Plasma Protein Binding 
Ramipril: About 73%. 
Ramiprilat: About 56%. 
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Metabolism 
Metabolized mainly in the liver, principally to an active metabolite, ramiprilat. 
 
Elimination Route 
Excreted in urine (60%) as unchanged drug and ramiprilat and in feces 
(approximately 40%). 
 
Half-life 
Triphasic; apparent elimination half-life of ramiprilat: Approximately 13–17 
hours. 
 
OVER DOSAGE 
May lead to severe hypotension. Normal saline infusion may be used for 
treatment. Overdose symptoms may include feeling extremely dizzy or light-headed, 
or fainting, excessive peripheral vasodilation with marked hypotension and shock, 
bradycardia, electrolyte disturbances, and renal failure. 
 
ROUTE OF ADMINISTRATION: oral. 
 
DOSAGE FORM/STRENGTH: 1.25 mg, 2.5mg, 5 MG,10mg. 
 
INDICATIONS: 
For the management of mild to severe hypertension. May be used to reduce 
cardiovascular mortality following myocardial infarction in hemodynamically stable 
individuals who develop clinical signs of congestive heart failure within a few days 
following myocardial infarction. To reduce the rate of death, myocardial infarction 
and stroke in individuals at high risk of cardiovascular events. May be used to slow 
the progression of renal disease in individuals with hypertension, diabetes mellitus 
and microalbuminuria or overt nephropathy. 
 
CONTRAINDICATIONS: 
Intestinal Angioedema, Head and Neck Angioedema, Method of Removing 
Waste/Poison from Blood with Dialysis, Renal Artery Stenosis, Liver Problems, 
Kidney Disease, Systemic Lupus Erythematosus, Scleroderma, Disorder of the 
Connective Tissue, Severe Vomiting, Severe Diarrhea, Kidney Problems Causing a 
Decreased Amount of Urine to be Passed, Azotemia, Abnormal Liver Function Tests, 
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Allergy Shots, Pregnancy, Low Amount of Sodium in the Blood, Extreme Loss of 
Body Water, High Amount of Potassium in the Blood, Inherited Disorder of 
Continuing Episodes of Swelling, Decreased Neutrophils a Type of White Blood Cell. 
 
WARNINGS: 
When used in pregnancy during the second and third trimesters, ACE 
inhibitors can cause injury and even death to the developing fetus. When pregnancy is 
detected, ramipril should be discontinued as soon as possible. Ramipril should be used 
with caution in: the elderly (particularly those taking diuretics or with heart failure, 
kidney or liver problems), those with poor liver or kidney function, patients taking 
diuretics, those who are dehydrated or on a low-salt diet, those undergoing dialysis or 
a form of blood treatment called apheresis, and children.  
 
PRECAUTIONS: 
Pregnancy 
Category D (second, third trimester); Category C (first trimester). Discontinue 
use in pregnant patients; fetal/neonatal injury and death have occurred. Closely 
observe infants with histories of in utero exposure. 
 
Hyperkalemia 
Possible hyperkalemia, especially in patients with renal impairment or 
diabetes mellitus and those receiving drugs that can increase serum potassium 
concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-
containing salt substitutes). 
 
Cough 
Persistent and nonproductive cough; resolves after drug discontinuance.  
 
Renal Impairment 
Systemic exposure to ramiprilat may be increased. Initial dosage adjustment 
may be necessary depending on degree of renal impairment33.  
 
ADVERSE DRUG REACTIONS: 
Nausea, vomiting, diarrhea, dizziness, fatigue, head ache, abdominal pain, 
cough, angioneuritic odema of face, lips, tongue, glottis and larynx, syncope, renal 
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impairment, hyper sensitivity reactions, severe hypotension and angioedema. Rarely 
symptomatic hypertension may occur. 
 
DRUG-DRUG INTERACTIONS: 
Angiotensin receptor blockers 
Combining ACE inhibitors (such as ramipril) with ARBs may increase the risk 
of various problems (such as kidney damage, high potassium levels, or dangerously 
low blood pressure) without providing significant benefit. In general, ramipril should 
not be combined with ARB medications. 
  
Diuretics 
If taking ramipril with a diuretic, blood pressure may decrease too much. The 
risk of this happening can be reduced by either stopping the diuretic (under a 
healthcare provider's supervision) or increasing salt intake prior to starting the 
ramipril.  
 
Injectable Gold 
Reactions have been reported in people taking ramipril who received gold 
injections. These reactions included symptoms such as facial flushing, nausea, 
vomiting, and low blood pressure. 
  
Lithium 
Ramipril may increase the risk of lithium toxicity and may increase the lithium 
levels in the blood. Blood lithium levels should be monitored to adjust the dose. 
 
Nonsteroidal Anti-Inflammatory Drugs  
Ramipril can interact with NSAIDS in several ways. The combination could 
cause blood pressure to increase or may cause swelling (edema), especially if have 
congestive heart failure (CHF). If elderly, have kidney disease or kidney failure, or 
are taking a diuretic or are dehydrated, taking NSAIDs and ramipril together may 
cause kidney failure.  
 
Potassium 
If taking a potassium product together with ramipril, the levels of potassium in 
blood may become too high. This can cause serious problems. 
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                                                TELMISARTAN 
 
BRAND NAME: TELMA, CREZAR, TAZLOC. 
 
CHEMICAL NAME: 4'-[(1,4'-dimethyl-2'-propyl [2,6'-bi-1H-benzimidazol]-1'-
yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid.  
 
CHEMICAL FORMULA: C33H30N4O2 
 
STRUCTURAL FORMULA: 
 
                                       
                                
 
 
DESCRIPTION: 
Telmisartan is a white to slightly yellowish solid. It is practically insoluble in 
water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble 
in hydrochloric acid), and soluble in strong base. 
 
DOSAGE FORM:  Tablet 
 
MECHANISM OF ACTION: 
Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-
receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and 
the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis 
and release of aldosterone, blockage of its effects results in decreases in systemic vascular 
                                        Drug profile 
 
34 
Dept. of Pharmacy Practice, K.M. College of Pharmacy, Madurai   
resistance. Telmisartan does not inhibit the angiotensin converting enzyme, other hormone 
receptors, or ion channels. Studies also suggest that telmisartan is a partial agonist of PPARγ, 
which is an established target for antidiabetic drugs. This suggests that telmisartan can 
improve carbohydrate and lipid metabolism, as well as control insulin resistance without 
causing the side effects that are associated with full PPARγ activators34. 
 
CLINICAL PHARMACOLOGY 
PHARMACODYNAMICS:    
Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts 
on the AT1 receptor subtype. It has the highest affinity for the AT1 receptor among 
commercially available ARBS and has minimal affinity for the AT2 receptor. New 
studies suggest that telmisartan may also have PPARγ agonistic properties that could 
potentially confer beneficial metabolic effects, as PPARγ is a nuclear receptor that 
regulates specific gene transcription, and whose target genes are involved in the 
regulation of glucose and lipid metabolism, as well as anti-inflammatory responses. 
This observation is currently being explored in clinical trials. Angiotensin II is formed 
from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, 
kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin 
system, with effects that include vasoconstriction, stimulation of synthesis and release 
of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan 
works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin 
II.  
 
PHARMACOKINETICS: 
 
Absorption 
Bioavailability 
Absolute bioavailability is dose dependent: 42% at 40 mg, 58% at 160 mg. 
Peak plasma concentration generally reached at 0.5–1 hour following oral 
administration. Antihypertensive effect evident within 2 weeks, with maximum BP 
reduction after 4 weeks35.Food slightly reduces bioavailability. In patients with 
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hepatic insufficiency, plasma telmisartan concentrations are increased and absolute 
bioavailability approaches 100%. 
 
Distribution 
Crosses the placenta and is distributed in the fetus in animals.  
Distributed into milk in rats; not known whether distributed into human milk.  
Plasma Protein Binding.  
 >99.5% (principally albumin and α1-acid glycoprotein).  
 
Metabolism 
Metabolized in liver (via conjugation) to inactive metabolite.  
Not metabolized by CYP isoenzymes.  
 
Elimination Route 
Eliminated mainly (>97%) as unchanged drug in feces (via bile); small 
amounts (<1%) eliminated in urine. 
 
Half-life 
Biphasic; terminal half-life is approximately 24 hours. 
 
OVER DOSAGE: 
Overdose symptoms may include fast or slow heartbeat, dizziness. The most 
likely manifestations of overdosage with telmisartan would be hypotension, dizziness 
and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. 
 
DOSAGE FORM/STRENGTH:  20 mg , 40 mg ,80 mg 
 
INDICATIONS: 
Used alone or in combination with other classes of antihypertensives for the 
treatment of hypertension. Also used in the treatment of diabetic nephropathy in 
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hypertensive patients with type 2 diabetes mellitus, as well as the treatment of 
congestive heart failure (only in patients who cannot tolerate ACE inhibitors). 
 
CONTRAINDICATIONS: 
  Renal Artery Stenosis, Abnormally Low Blood Pressure, Liver Problems, 
Blockage of a Bile Duct, Kidney Disease, Pregnancy, Decreased Blood Volume, 
Extreme Loss of Body Water, High Amount of Potassium in the Blood. 
 
WARNINGS: 
            When used in pregnancy, drugs that act directly on the renin-angiotensin 
system can cause injury and even death to the developing fetus. When pregnancy is 
detected, ramipril should be discontinued as soon as possible. If oligohydramnios is 
observed, ramipril tablets should be discontinued unless they are considered life-
saving for the mother. Infants with histories of in utero exposure to an angiotensin II 
receptor antagonist should be closely observed for hypotension, oliguria, and 
hyperkalemia. 
 
PRECAUTIONS: 
Telmisartan may cause extreme low blood pressure in some people. Extreme 
low blood pressure is more likely to happen in people who are taking a diuretic, are 
on dialysis, or have congestive heart failure. 
 
Telmisartan is a pregnancy Category C medicine for the first trimester and a 
pregnancy Category D medicine for the second and third trimesters, meaning that it 
poses potential health risks to your unborn child. 
 
While taking telmisartan, do not use potassium supplements or salt substitutes 
with potassium unless you have discussed this with your doctor. 
 
This medication may cause a decrease in kidney function, especially in people 
who are elderly, have kidney disease, have severe congestive heart failure (CHF), or 
are taking nonsteroidal anti-inflammatory drugs (NSAIDs) or diuretics (water pills). 
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ADVERSE DRUG REACTIONS: 
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the 
chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); change in the 
amount of urine produced or painful urination; chest pain; difficulty swallowing; fast, 
slow, or irregular heartbeat; fever, chills, or persistent sore throat; increased or 
excessive sweating; muscle pain or cramps; severe or persistent vomiting or diarrhea; 
severe or persistent weakness; shortness of breath; swelling of the arms or legs; 
symptoms of low blood pressure (eg, fainting, lightheadedness, severe dizziness); 
tendon or joint pain36. 
 
DRUG-DRUG INTERACTIONS: 
           With telmisartan, drugs such as potassium supplements or potassium-sparing 
diuretics may cause an interaction. Not only can drug interactions with telmisartan 
cause body to metabolize the medicines differently than intended, but they may also 
result in side effects such as extremely low blood pressure or excessive drug levels in 
your blood. 
Concurrent use increases digoxin concentration; increases risk of lithium toxicity; 
increases risk of hyperkalaemia with potassium sparing diuretics, heparin37.  
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LITERATURE REVIEW 
1. Italo Proto38et al. compared the effects of ramipril and telmisratan on high 
sensitivity c-reactive protein and endothelial progenitor cells after acute 
coronary syndrome.42 patients with ACS were randomized after successful 
percutaneous coronary intervention to ramipril 5 mg/day (22 patients) or 
telmisartan 80 mg/day (20 patients). Peripheral blood samples were drawn at 
baseline and at 20 days to measure high-sensitivity C-reactive protein               
and to assess 4 populations of progenitor cells by flow cytometry,                    
namely CD34+/KDR+, CD34+/CD133+ CD34+/CD133+/CD45-, and 
CD34+/KDR+/CD45- cells CD34+/KDR+/CD45- cells. High-sensitivity C-
reactive protein levels, similar in the 2 groups at baseline, were significantly 
more decreased by telmisartan than by ramipril at follow up (p = 0.013 for 
time-by-drug interaction). The main effect for time was also significant (p 
<0.001). CD34+/KDR+ and CD34+/CD133+ cells were similar at baseline and 
did not change over time (p = 0.2 and p = 0.1, respectively). In contrast, for 
CD34+/KDR+/CD45- and CD34+/CD133+/CD45- cells, a significant increase 
with time was seen (p = 0.02 and p = 0.002, respectively) and no differential 
effect of either drug was seen. In conclusion, telmisartan shows a more potent 
anti-inflammatory effect than ramipril after an ACS. The 2 drugs do not show a 
differential effect on endothelial progenitor cell mobilization. 
 
2. Myung Ho Jeong 39 et al. studied relation between High-Sensitivity C-
Reactive Protein and Coronary Plaque Components in Patients With Acute 
Coronary Syndrome. Virtual histology-intravascular ultrasound (VH-IVUS) is 
used to evaluate the relationship between high-sensitivity C-reactive protein 
levels and plaque components in 279 acute coronary syndrome patients.Patients 
are divided into three groups according to their hs-CRP levels {lowest tertile 
<0.07 mg/dL (n=93), middle tertile ≥0.07, <0.4 mg/dL (n=93), and highest 
tertile ≥0.4 mg/dL (n=93)}. Thin-cap fibroatheroma (TCFA) was defined as 
focal, necrotic core (NC)-rich (≥10% of the cross-sectional area) plaques in 
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contact with the lumen in a plaque burden ≥40%.The highest tertile group was 
mostly diabetics (20%, 27%, 40%, p=0.009), and had the greatest plaque plus 
media volume (163±139/mm3 vs. 201±155/mm3 vs. 232±176/mm3, p=0.013). 
The highest tertile group had the greatest absolute and % NC volumes 
(13.6±15.1 mm3 vs. 14.8±14.2 mm3 vs. 23.7±24.3 mm3, p<0.001, and 
14.9±8.7% vs. 16.0±8.7% vs. 19.5±10.2%, p=0.024, respectively). The culprit 
lesion TCFA was observed most frequently in the highest tertile group (28% 
vs. 35% vs. 55%, p=0.006). By multivariable analysis, absolute NC volume 
was an independent predictor of hs-CRP elevation {odds ratio (OR); 1.03, 95% 
confidence interval (CI)=1.06-1.21, p=0.004}, and hs-CRP was an independent 
predictor of TCFA (OR; 1.86, 95% CI=1.11-2.90, p=0.010).VH-IVUS analysis 
has demonstrated that ACS patients with elevated hs-CRP have more 
vulnerable plaque component  compared with ACS patients with normal hs-
CRP. 
 
3. Deborah B Diercks 40et al. compared the Value of high-sensitivity C-reactive 
protein in low risk chest pain observation unit patients. A total of 958 patients 
had hs-CRP testing as part of their CPEU evaluation. Excluded from the 
analysis were 39 patients lost to follow-up. The final cohort comprised 478 
(52%) women and 441 (48%) men with a median age of 56 (IQR 48-64). ACS 
was diagnosed in 128 (13.4%). The median cohort hs-CRP value was 2.2 mg/l 
(IQR 0.7, 5.8) and 2.3 mg/l (IQR 0.6, 5.9) in those with and without ACS, 
respectively. In the multivariate analysis hs-CRP was not independently 
associated with the diagnosis of ACS (0.99; 95% CI 0.98 - 1.01). In large 
patient cohort managed in a single-center CPU, measurement of hs-CRP did 
not enhance the diagnostic accuracy for ACS. Routine hs-CRP as a diagnostic 
tool should not be recommended in the CPU setting. 
 
4. Riedel M41et al. suggested that High-sensitivity C-reactive protein has been 
reported to have a prognostic value immediately after acute coronary syndrome 
and to be associated with the onset of cardiovascular events in patients with 
stable and unstable angina pectoris. Aim is to evaluate whether or not hsCRP 
levels can be used to predict future CV events in a prospective study of post-
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ACS patients receiving an optimized medical treatment (OMT) secondary-
prevention regimen. Methods: OMT along with therapeutic and dietary 
education programmes were started during the acute phase, then monitored and 
adjusted as needed at 3 months post ACS. hsCRP was measured at 3 months 
after the ACS, and a global evaluation of atherosclerosis burden and risk 
factors were also evaluated at this time point. The study population was divided 
into tertiles based on their hsCRP value and followed for CV events. Results: A 
total of 1202 consecutive patients with hsCRP <15 mg/l were included in the 
study, 795 of which were followed for an average of 22 months. LDL-
cholesterol, HbA(1c), waist circumference, systolic blood pressure, metabolic 
syndrome, tobacco consumption, and atherosclerosis burden were higher in 
patients in the second and third tertile of hsCRP (p < 0.001) than those in the 
first tertile, at 3 months. hsCRP level was not found to be associated with 
recurrence of total CV events in univariate analysis. We further examined the 
effect of adding hsCRP levels to the Framingham risk evaluation score, and 
found no significant improvement the C-statistics of the Framingham risk 
evaluation score. Conclusion: hsCRP is associated with CV risk factors, but is 
not an independent predictor of future events in post-ACS patients receiving an 
OMT secondary-prevention regimen. 
 
5. Puri VK42et al. suggested that Percutaneous coronary intervention provokes an 
inflammatory reaction, as shown by increased concentrations of plasma C-
reactive protein after PCI. However, the changes of CRP levels after PCI in 
patients with acute coronary syndrome have not been well evaluated. They 
evaluated the characteristics of the patients with elevated CRP response after 
PCI and whether an increase in CRP after PCI predicts long-term prognosis in 
patients with ACS. We studied consecutive 360 patients with ACS who 
underwent elective coronary stenting. Inflammatory response to PCI was 
calculated as the difference between the peak postprocedural hsCRP level and 
the preprocedural hsCRP level (ΔCRP). Twelve months follow-up data were 
obtained and clinical outcomes were compared with ΔCRP. In receiver 
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operating characteristics analyses, the cutoff point of ΔCRP for major adverse 
cardiac events was 3.0 mg/l, which yielded sensitivity of 61.7% and specificity 
of 69.7%. The patients with ΔCRP > 3 mg/l revealed higher incidence of 
myocardial infarction (37.7 vs 14.6%, P < 0.001), and ACC/AHA type B2/C 
lesion (81.5 vs 68.7%, P = 0.006) than in patients with low ΔCRP. White blood 
cell count, low-density lipoprotein cholesterol, peak creatinine kinase-MB, and 
peak troponin T were significantly elevated in patients with ΔCRP > 3 mg/l 
than in those with ≤3 mg/l. There was significant correlation between ΔCRP 
and the changes in troponin T after PCI (r = 0.210, P < 0.001). An increase in 
hsCRP > 3 mg/l after PCI had a higher predictive value for the occurrence of 
MACE than low hsCRP elevation (hazard ratio 2.1, P = 0.005). In multivariate 
analysis, ΔCRP and peak troponin T were independent predictors of MACE (P 
< 0.001 and P = 0.013, respectively). In conclusion, postprocedural hsCRP 
elevation >3 mg/l was associated with higher incidence of MACE in patients 
with ACS. ΔCRP determinations may be of value for risk stratification after 
PCI. 
 
6. Sethi R43 et al. demonstrated correlation between high sensitivity C-reactive 
protein and socio-economic class in patients of acute coronary syndrome.Mean 
levels of hs-CRP in lower, middle and upper SES were 2.3 +/- 2.1 mg/L, 0.8 
+/- 1.7 mg/L and 1.2 +/- 1.5 mg/L, respectively. hs-CRP levels were 
significantly higher in low SES compared with both upper SES (p = 0.033) and 
middle SES (p = 0.001). Prevalence of more than one traditional CAD risk 
factors was seen in 13.5%, 37.5% and 67.67 percent; in patient of lower, 
middle and upper SES. It was observed that multiple risk factors had a linear 
correlation with increasing SES. Of the four traditional risk factors of CAD, 
smoking was the only factor which was significantly higher in lower SES 
(73%) as compared to middle (51.67 percent;) and upper (39.4%) SES. We 
found that 62.3%, 20.8% and 26.5% patients of low, middle and upper SES had 
hs-CRP values in the highest tertile. Median value of the Framingham risk 
score in low, middle and upper SES as 11, 14 and 18, respectively. We 
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observed that at each category of Framingham risk, low SES had higher hs-
CRP.Conclusion from the study is that patient of lower SES have significantly 
higher levels of hs-CRP despite the fact that they have lesser traditional risk 
factors and lower Framingham risk. These findings add credit to our belief that 
inflammation may be an important link in the pathophysiology of 
atherosclerosis and its complications especially in patients of low SES who do 
not have traditional risk factors. 
 
7. Torres JL44 et al. studied the importance of High sensitivity C-reactive protein 
in clinical practice.As a growing number of patients with low low-density 
lipoprotein cholesterol levels are diagnosed with atherosclerosis, research has 
shifted toward markers of inflammation in an attempt to improve global 
cardiovascular risk prediction. These markers include cytokines, cell adhesion 
molecules, and acute phase reactants like high sensitivity C-reactive protein, an 
innate immune response protein. When measured with new high-sensitivity 
assays, levels of high sensitivity C-reactive protein have proven to predict 
future cardiovascular risk at all levels of low-density lipoprotein cholesterol, at 
all levels of the Framingham Risk Score, and at all levels of the metabolic 
syndrome. Among apparently healthy men and women, levels of high 
sensitivity C-reactive protein of <1, 1-3, and >3 mg/L distinguish between 
those at low, moderate, and high risk for future cardiovascular disease, 
respectively. In clinical practice, high sensitivity C-reactive protein should be 
used along with lipid evaluation as part of global risk assessment. Improved 
knowledge of cardiovascular risk should lead to improved compliance with 
both lifestyle and pharmacologic interventions designed to prevent future 
cardiovascular events. 
 
8. Hannes F45 et al. studied the role of inflammation in the pathophysiology of 
acute coronary syndromes. All stages of atherosclerotic plaques are 
characterized by an inflammatory component, in which T lymphocytes and 
macrophages orchestrate lesion progression and destabilization by releasing 
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cytokines (e.g., interferon-gamma, tumor necrosis factor-alpha, tissue factor). 
At the extreme end of this process plaque rupture occurs, which may manifest 
clinically as an acute coronary syndrome. Hence, measuring this 
atherosclerosis-inherent inflammation may help predicting cardiovascular 
events. Accordingly, different soluble inflammatory markers were studied for 
their predictive value in acute coronary syndromes. Special attention was paid 
to high-sensitivity C-reactive protein (hs-CRP) and soluble CD40 ligand 
(sCD40L). The latter seems not only to be a marker of inflammation and 
platelet activation, but is suggested to directly destabilize atherosclerotic 
plaques by stimulating pro-inflammatory T lymphocytes. Therefore, reduction 
of soluble inflammatory markers is an attractive target for future therapeutic 
strategies. Statins and glycoprotein IIb/IIIa antagonists, well-established 
treatments in acute coronary syndromes, were demonstrated to decrease hs-
CRP and sCD40L. Whether this reduction translates into a better prognosis has 
to be investigated in further studies. 
 
9. Shishehbor MH46 et al proved that Inflammation plays a pivotal role in all 
stages of atherogenesis, from foam cell to plaque formation to rupture and 
ultimately to thrombosis. Insight gained from recent basic and clinical data 
linking inflammation to atherosclerosis has yielded important diagnostic and 
prognostic information. Low-grade chronic inflammation as measured by high 
sensitivity C-reactive protein predicts future risk of acute coronary syndrome 
independent of traditional cardiovascular risk factors. In addition, individuals 
with higher "inflammatory burden" gain the largest absolute risk reduction with 
aggressive risk-lowering therapy. The link between inflammation and 
atherosclerosis provides a new venue for future pharmacologic agents that may 
slow the progression of atherosclerosis by inhibiting inflammation. 
 
10. Matsumoto D47et al. suggested that Elevated circulating C-reactive protein is 
commonly observed in patients with acute coronary syndrome suggesting 
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enhanced inflammation in vulnerable plaques. However, few data are available 
on the relationship between the levels of CRP and the histological composition 
of coronary plaque. They investigated the relationship between plasma high 
sensitive CRP level and coronary plaque component with Virtual Histology 
intravascular ultrasound (VH-IVUS).IVUS spectral analysis revealed that 
elevated plasma high sensitve CRP level was correlated with necrotic core 
volume in patients with ACS, both in culprit and non-culprit lesions, suggesting 
enhanced vascular inflammation. 
 
 [ [[ 
11. White CM48et al. suggested that Standard therapies for the management of 
stable ischemic heart disease partially reduce the risk of a future acute coronary 
syndrome. Among patients with chronic heart failure or previous myocardial 
infarction and left ventricular dysfunction, a large body of evidence supports 
the benefits of angiotensin-converting enzyme inhibitors or angiotensin-II 
receptor blockers and, in heart failure, combined therapy with these agents. In 
contrast, there is less certainty regarding outcomes of ACE inhibitors and 
ARBs for people with stable IHD who have preserved left ventricular function 
and no signs or symptoms of heart failure.  
 
 
12. Ram C49et al. proposed that Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers have shown cardioprotective and renoprotective 
properties. These agents are recommended as first-line therapy for the 
treatment of hypertension and the reduction of cardiovascular risk. Early 
studies pointed to the cardioprotective and renoprotective effects of ARBs in 
high-risk patients. The ongoing Telmisartan Alone and in combination with 
ramipril global endpoint Trial (ONTARGET) established the clinical 
equivalence of the cardioprotective and renoprotective effects of telmisartan 
and ramipril, but did not find an added benefit of the combination over ramipril 
alone. Similar findings were observed in the Telmisartan Randomized 
Assessment Study in ACE Intolerant subjects with cardiovascular Disease 
(TRANSCEND) trial conducted in ACEI-intolerant patients. In ONTARGET, 
telmisartan had a better tolerability profile with similar renoprotective 
properties compared with ramipril, suggesting a potential clinical benefit over 
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ramipril. The recently completed Olmesartan reducing Incidence of endstage 
renal disease in diabetic nephropathy Trial (ORIENT) and Olmesartan and 
Calcium Antagonists Randomized (OSCAR) studies will further define the role 
of ARBs in cardioprotection and renoprotection for high-risk patients. 
 
 
13. Frampton JE50 et al.suggested that Telmisartan a well established angiotensin 
type 1 receptor antagonist, is indicated in the EU for the reduction of 
cardiovascular morbidity in patients with manifest atherothrombotic 
cardiovascular disease or type 2 diabetes mellitus with documented target organ 
damage, as well as for the treatment of hypertension. In the pivotal 
ONTARGET trial, which enrolled ACE inhibitor-tolerant patients at high 
vascular risk, telmisartan 80Ԝmg once daily added to existing, proven therapy 
was noninferior to ramipril 10Ԝmg once in terms of CVD prevention. Moreover, 
telmisartan was better tolerated than ramipril, as reflected in, for example, 
lower incidences of permanent treatment discontinuations due to cough and 
angioedema. The placebo-controlled TRANSCEND and PROFESS studies 
provided supporting evidence for the effectiveness of telmisartan in preventing 
cardiovascular events, although the drug appeared to have neither a beneficial 
nor a harmful impact on cardiovascular mortality. The TRANSCEND trial also 
demonstrated that telmisartan was well tolerated in ACE inhibitor-intolerant 
patients at high vascular risk. On the basis of these findings, telmisartan can be 
considered as an effective treatment option for CVD prevention in patients at 
high vascular risk. Consideration may be given to prescribing the drug as an 
alternative to ramipril in patients who are able to tolerate ACE inhibitors and 
potentially instead of ramipril in patients who are unable to tolerate ACE 
inhibitors. 
 
 
14. Domenico Galzerano51et al. suggested that Blockade of the renin–angiotensin 
system is an important approach in managing high blood pressure and has 
increasingly been shown to affect cardiovascular disease processes mediated by 
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angiotensin II throughout the cardiovascular and renal continua. Telmisartan is 
an angiotensin II receptor blocker displaying unique pharmacologic properties 
including a longer half life than any other ARB that result in large and 
sustained reductions of blood pressure. In patients with mild-to-moderate 
hypertension, telmisartan has proved superior to other antihypertensive agents 
(valsartan, losartan, ramipril, perindopril, and atenolol) in controlling blood 
pressure particularly towards the end of the dosing interval. There is also 
clinical evidence that telmisartan reduces left ventricular hypertrophy, reduces 
arterial stiffness and the recurrence of atrial fibrillation, and confers 
renoprotection. The ongoing Telmisartan alone and in combination with 
Ramipril global endpoint trial (ONTARGET®) study has demonstrated that 
telmisartan has similar cardiovascular protective effects to ramipril in a large, 
high-risk patient population but was better tolerated. The powerful and 
sustained blood pressure control apparent in clinical trials, together with 
cardiovascular protection and tolerability demonstrated in ONTARGET® 
means that telmisartan may be a preferred option for patients with 
hypertension. 
 
15. Ramón C52 et al. proposed that Clinical studies have demonstrated a different 
effect on blood pressure of some angiotensin-converting enzyme inhibitors 
when administered in the morning versus the evening. Their administration at 
bedtime resulted in a higher effect on nighttime blood pressure as compared 
with morning dosing. This study investigated the administration time-
dependent effects of ramipril on ambulatory blood pressure. They studied 115 
untreated hypertensive patients, 46.7±11.2 years of age, randomly assigned to 
receive ramipril (5 mg/d) as a monotherapy either on awakening or at bedtime. 
Blood pressure was measured for 48 hours before and after 6 weeks of 
treatment. The blood pressure reduction during diurnal activity was similar for 
both treatment times. Bedtime administration of ramipril, however, was 
significantly more efficient than morning administration in reducing asleep 
blood pressure. The awake:asleep blood pressure ratio was decreased after 
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ramipril on awakening but significantly increased toward a more dipping 
pattern after bedtime dosing. The proportion of patients with controlled 
ambulatory blood pressure increased from 43% to 65% (P=0.019) with bedtime 
treatment. Nocturnal blood pressure regulation is significantly better achieved 
at bedtime as compared with morning administration of ramipril, without any 
loss in efficacy during diurnal active hours. This might be clinically important, 
because nighttime blood pressure has been shown to be a more relevant marker 
of cardiovascular risk than diurnal mean values. The change in the dose-
response curve, increased proportion of controlled patients, and improved 
efficacy on nighttime blood pressure with administration of ramipril at bedtime 
should be taken into account when prescribing this angiotensin-converting 
enzyme inhibitor for treatment of essential hypertension. 
[[ 
16. Paweł Petkow-Dimitrow53et al. suggested that Angiotensin-converting 
enzyme inhibitors and angiotensin receptor blockers posses multiple beneficial 
effects such as cardioprotection, cerebroprotection, nephroprotection which 
provide opportunity to select the most suitable drug for the target vascular bed 
(e.g. coronary, or cerebral circulation). In some clinical settings, combined 
therapy ACE-I with ARB (double blockage of the renin-angiotensin- -
aldosteron system) may appear the most effective. These drugs (especially 
ARB) may successfully prevent atrial fibrillation and play a protective role in 
metabolic syndrome. Recently, it has been demonstrated that losartan is able to 
inhibit vasodilatation of the aorta in marfan syndrome, which might prevent 
sudden death due to aorta rupture. An increasing role of ARB is most beneficial 
in hipotensive therapy (inhibition/regression of hypertension-related organ 
damage). With particular interest, results of the ONTARGET study are being 
awaited. This study is focused on the effect of double blockage (ramipril and 
telmisartan) on reduction of the occurrence of myocardial infarction, stroke, 
and heart failure.  
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17. Philippe Gosse54 et al. made a review that measurement of blood pressure in 
the clinic may provide a false impression of blood pressure control. 
Ambulatory blood pressure monitoring (ABPM) allows the automatic recording 
of the circadian variation in blood pressure and evaluation of the efficacy of 
antihypertensive medication throughout the dosing interval. Ambulatory blood 
pressure provides more effective prediction of cardiovascular risk; blood 
pressure control at the time of heightened risk in the early morning after 
walking and before taking the next dose of medication is becoming important 
in order to improve long-term prognosis. To achieve blood pressure control in 
the early morning, a long-acting antihypertensive agent is essential. 
Telmisartan, an angiotensin II receptor blocker, as well as having a terminal 
elimination halflife of 24 h, has a large volume of distribution due to its high 
lipophilicity. The efficacy of telmisartan 80 mg monotherapy has been 
demonstrated using ABPM, with superior reduction in mean values for the last 
6 h of the dosing interval compared with ramipril 10 mg and valsartan 80 mg. 
In addition, telmisartan 80 mg provides superior blood pressure control after a 
missed dose compared with valsartan 160. When combined with 
hydrochlorothiazide (HCTZ) 12.5 mg, telmisartan 40 mg and 80 mg is more 
effective than losartan/HCTZ (50/12.5 mg) at the end of the dosing interval. 
Furthermore, greater reductions in last 6 h mean systolic blood pressure (SBP) 
and diastolic blood pressure (DBP) are achieved with telmisartan/HCTZ 
(80/12.5 mg) than with valsartan/HCTZ (160/12.5 mg) in obese patients with 
type 2 diabetes and hypertension. Recent data from a large group of patients 
show that telmisartan 80 mg controls the early morning blood pressure surge 
more effectively than ramipril 5–10 mg and, thus, may have a greater beneficial 
effect on long-term cardiovascular risk. This supposition is being tested in the 
ongoing Telmisartan alone and in combination with ramipril global endpoint 
trial (ONTARGET) programme. 
 
18. Christiano argano55 et al. studied the effects of 24 weeks losartan and ramipril 
treatment, both alone and in combination, on blood pressure and left ventricular 
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mass (LVM) and function, have been evaluated in hypertensives.57 
hypertensives with stage 1 and 2 essential hypertension were included. After 4 
weeks run in, a randomized double-blind, 3 arm, double dummy, independent 
trial was used. All patients were randomly allocated to 3 treatment arms 
consisting of losartan (50 mg/daily), ramipril (5 mg/daily), and combined 
(losartan 50 mg/ramipril 5 mg/daily) for 24 weeks. LVM, LVM/h and other 
echocardiographic measurements, BUN, creatinine and clearance and 
potassium were determined after run in and 24 weeks.All groups were 
comparable for gender, age, BMI, BP and LVM. The prevalence of baseline 
left ventricular hypertrophy (LVH) was not significantly different among 3 
groups. At the end of treatment, a significant (p<0.05) reduction in SBP, DBP, 
MBP, LVM and LVM/h were observed in all groups. The absolute and percent 
reductions in LVM/h were significantly higher in combined than losartan or 
ramipril groups and also in hypertensives with LVH. No significant change in 
absolute and percent reduction of SBP, DBP and MBP were found.These data 
indicate an additional cardioprotective effect of dual blockade of RAS in 
hypertensive patients with and without left ventricular hypertrophy. 
 
19. Farsang C56 et al. suggested that antihypertensive agents are widely used to 
reduce the risk of cardiovascular events partly beyond that of blood pressure-
lowering. In particular, the angiotensin II receptor blockers (ARBs), which 
antagonize the vasoconstrictive and proinflammatory/pro-proliferative effects 
of angiotensin II, have been shown to be cardio vascularly protective and well 
tolerated. Although the eight currently available ARBs are all indicated for the 
treatment of hypertension, they have partly different pharmacology, and their 
pharmacokinetic and pharmacodynamic properties differ. ARB trials for 
reduction of cardiovascular risk can be broadly categorized into those in 
patients with/without hypertension and additional risk factors, in patients with 
evidence of cardiovascular disease, and in patients with severe cardiovascular 
disease, such as heart failure. These differences have led to their indications in 
different populations. For hypertensive patients with left ventricular 
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hypertrophy, losartan was approved to have an indication for stroke prevention, 
while for most patients at high-risk for cardiovascular events, telmisartan is an 
appropriate therapy because it has a cardiovascular preventive indication. Other 
ARBs are indicated for narrowly defined high-risk patients, such as those with 
hypertension or heart failure. Although in one analysis a possible link between 
ARBs and increased risks of cancer has surfaced, several meta-analyses, using 
the most comprehensive data available, have found no link between any ARB, 
or the class as a whole, and cancer. Most recently, the US Food and Drug 
Administration completed a review of the potential risk of cancer and 
concluded that treatment with an ARB medication does not increase the risk of 
developing cancer. This review discusses the clinical evidence supporting the 
different indications for each of the ARBs and the outstanding safety of this 
drug class. 
 
20. Bodh I Jugdut57 et al. proposed that elderly patients (age≥65 years) with 
hypertension are at high risk for vascular complications, especially when 
diabetes is present. Antihypertensive drugs that inhibit the renin-angiotensin 
system have been shown to be effective for controlling blood pressure in adult 
and elderly patients. Importantly, renin-angiotensin system inhibitors were 
shown to have benefits beyond their classic cardioprotective and 
vasculoprotective effects, including reducing the risk of new-onset diabetes and 
associated cardiovascular effects. The discovery that the renin-angiotensin 
system inhibitor and angiotensin II type 1 (AT1) receptor blocker, telmisartan, 
can selectively activate the peroxisome proliferator-activated receptor-γ 
provides the unique opportunity to prevent and treat cardiovascular 
complications in high-risk elderly patients with hypertension and new-onset 
diabetes. Two large clinical trials, ONTARGET (Ongoing telmisartan alone in 
combination with ramipril global endpoint trial) and TRANSCEND 
(Telmisartan Randomized Assessment Study in ACE-I intolerant subjects with 
cardiovascular disease) have assessed the cardioprotective and antidiabetic 
effects of telmisartan. The collective data suggest that telmisartan is a 
Literature Review  
51 
 Dept. of Pharmacy Practice, K.M. College of Pharmacy, Madurai   
 
promising drug for controlling hypertension and reducing vascular risk in high-
risk elderly patients with new-onset diabetes. 
 
21. Werner c58 et al. suggested that the combined use of angiotensin converting 
enzyme inhibitors and angiotensin receptor blockers posses a dilemma to 
clinicians. On the one hand, indirect evidence from compelling, but still 
surrogate outcome measures such as blood pressure and proteinuria suggest 
some merits of this combination. On the other hand, the outcome benefits of the 
ACEIs+ARBs combination in morbidity/mortality trials remain confined to 
patients with severe congestive heart failure (CHF) and reduced ejection 
fraction. Incidentally, most of the benefit offered by the ACEIs+ARBs 
combination in these patients was not driven by mortality, but by fewer 
rehospitalizations for CHF. Even in patients with renal disease and proteinuria, 
the combined use of ACEIs and ARBs, although highly effective in reducing 
urinary protein excretion, has not yet been proven to significantly delay end-
stage renal disease and the need for dialysis. In the Ongoing Telmisartan Alone 
and In Combination With Ramipril Global Endpoint Trial (ONTARGET), the 
dual blockade of the renin angiotensin system did not produce additional 
outcome benefit over that afforded by ACE inhibition alone. Notably, however, 
patients with BP >160/100 mmHg at entry were excluded from ONTARGET, 
thus limiting the applicability of these results to the treatment of hypertension. 
The European Society of Hypertension guidelines do not suggest large-scale 
use of the ACEIs+ARBs combination in patients with hypertension. However, 
patients with resistant hypertension, particularly if proteinuria coexists, could 
benefit from this combination, which however requires close monitoring for 
adverse events, including hyperkalemia and worsening renal function. 
 
22. Zou Z59 et al. proposed that Telmisartan and angiotensin-converting enzyme 
inhibitors are both effective and widely used antihypertensive drugs targeting 
renin-angiotensin-aldosterone system. The study aimed to estimate the efficacy 
and tolerability of telmisartan in comparison with different ACEIs as 
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monotherapy in the treatment of hypertension. Cochrane Central Register of 
Controlled Trials, PubMed and Embase were searched for relevant studies. A 
meta-analysis of all randomized controlled trials fulfilling the predefined 
criteria was performed. A random-effect model was used to account for 
heterogeneity among trials. Twenty-eight randomized controlled trials 
involving 5157 patients were ultimately identified out of 721 studies. 
Telmisartan had a greater diastolic blood pressure (DBP) reduction than 
enalapril (weighted mean difference (WMD) 1.82, 95% confidence interval 
(CI) 0.66-2.99), ramipril (WMD 3.09, 95% CI 1.94-4.25) and perindopril 
(WMD 1.48, 95% CI 0.33-2.62). Telmisartan also showed a greater DBP 
response rate than enalapril (relative risk (RR) 1.15, 95% CI 1.05-1.26), 
ramipril (RR 1.34, 95% CI 1.11-1.61) and perindopril (RR 1.22, 95% CI 1.05-
1.41). There was no statistical difference in DBP reduction or therapeutic 
response rate between telmisartan and lisinopril (WMD -0.30, 95% CI -0.65 to 
0.05; RR 0.99, 95% CI 0.80-1.23, respectively). Telmisartan had fewer drug-
related adverse events than enalapril (RR 0.57, 95% CI 0.44-0.74), ramipril 
(RR 0.44, 95% CI 0.26-0.75), lisinopril (RR 0.70, 95% CI 0.56-0.89) and 
perindopril (RR 0.52, 95% CI 0.28-0.98). The meta-analysis indicates that 
telmisartan provides a superior BP control to ACEIs (enalapril, ramipril and 
perindopril) and has fewer drug-related adverse events and better tolerability in 
hypertensive patients.  
 
 
23. Luis M. Ruilope60 et al.suggested that Cardiovascular disease places a 
significant burden on healthcare providers. High blood pressure is the single 
most prevalent risk factor for CVD worldwide and is responsible for more 
deaths than any other risk factor. ‘Cardiovascular high-risk patients’ make up 
the broad cross-section of patients in the middle of the risk spectrum for CVD 
progression that is referred to as the CV continuum and includes those with 
atherothrombotic disease, those with target organ damage associated with type 
2 diabetes and those with multiple risk factors. Angiotensin II is involved in 
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CVD progression at every stage of the CV continuum, making the renin–
angiotensin system a rational target for pharmacologic intervention. 
Angiotensin II receptor blockers offer a better tolerated alternative to 
angiotensin converting enzyme inhibitors, with greater long-term adherence. 
The ARB telmisartan recently received an indication for CV prevention. 
 
24. Yves Lacourcière61 et al. proposed that Blood pressure has a circadian pattern 
with a morning surge that is associated with an increased risk of acute coronary 
and cerebrovascular events. In a prospective, randomized, open-label, blinded-
endpoint, parallel-group, multicenter, forced-titration study of telmisartan and 
ramipril, the efficacy of both drugs on mean ambulatory diastolic BP (DBP) 
and systolic BP (SBP) during the last 6 h of a 24-h dosing interval was 
evaluated. Telmisartan 80 mg was consistently more effective than ramipril 10 
mg in reducing both DBP and SBP during the last 6 h of the dosing interval, a 
measure of the early morning period when patients are at greatest risk of life-
threatening cardiovascular and cerebrovascular events. Telmisartan 80 mg was 
also more effective than ramipril 10 mg in reducing BP throughout the entire 
24-h dosing interval. Both drugs were well tolerated. 
25. Deirdree A Lan62 et al. suggested that Peripheral arterial disease (PAD) 
causes considerable morbidity and mortality. Hypertension is a risk factor 
for  PAD.  Treatment  for  hypertension  must  be  compatible  with the 
symptoms of PAD. Controversy regarding the effects of beta-blockade for 
hypertension in patients with PAD has led many physicians to stop prescribing 
beta-blockers. Little is known about the effects of other classes of anti-
hypertensive drugs in the presence of PAD Four studies were included. Two 
compared ACE inhibitors against placebo. In the HOPE study there was a 
significant reduction in the number of cardiovascular events in 168 
patients receiving ramipril (OR 0.72, 95% confidence interval 0.58 to 0.91). In 
the second trial using perindopril in a small numbers of patients, there was a 
marginal increase in claudication distance but no change in ankle brachial 
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pressure index (ABPI) and a reduction in maximum walking distance.The third 
trial in patients undergoing angioplasty suggested that the calcium antagonist 
verapamil reduced restenosis, although this was not reflected in the 
maintenance of a high ABPI. Another small study demonstrated no significant 
difference in arterial intima-media thickness with men receiving the thiazide 
diuretic hydrochlorathiazide compared to those receiving the alpha-
adrenoreceptor blocker doxazosin.Evidence on various anti-hypertensive drugs 
in people with PAD is poor so that it is unknown whether significant benefits or 
risks accrue from their use. Lack of data specifically examining outcomes in 
PAD patients should not detract from the compelling evidence of the benefit of 
treating hypertension and lowering blood pressure. 
 
26. Anna A63 et al. suggested that Ramipril improves cardiovascular outcome in 
patients with peripheral arterial disease; however, the precise mechanisms of 
benefit remain to be elucidated. The effect of ramipril on large-artery stiffness 
in patients with peripheral arterial disease was examined. In addition, they 
determined the effect of ramiprilat on extracellular matrix from human aortic 
smooth muscle cell culture. 40 patients with peripheral arterial disease were 
randomized to receive ramipril, 10 mg once daily or placebo for 24 weeks. 
Arterial stiffness was assessed globally via systemic arterial compliance and 
augmentation index (carotid tonometry and Doppler velocimetry), and 
regionally via carotid–femoral pulse wave velocity. Angiotensin-converting 
enzyme inhibition increased arterial compliance by 0.10±0.02 mL/mm Hg, 
(P<0.001, all probability values relative to placebo) and reduced pulse wave 
velocity by 1.7±0.2 m/s (P<0.001), augmentation index by 4.1±0.3% 
(P<0.001), and systolic blood pressure by 5±1 mm Hg (P<0.001). Ramipril did 
not reduce mean arterial pressure significantly compared with placebo 
(P=0.59). In cell culture, ramiprilat decreased collagen deposition by >50% and 
increased elastin and fibrillin-1 deposition by >3- and 4-fold respectively. 
Fibrillin-1 gene expression was increased 5-fold). Ramiprilat also reduced gene 
and protein expression of both matrix metalloproteinase (MMP)-2 and MMP-3. 
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In conclusion, ramipril promoted an elastogenic matrix profile that may 
contribute to the observed clinical reduction in large-artery stiffness and carotid 
pressure augmentation, which occurred independently of mean arterial blood 
pressure reduction in patients with peripheral arterial disease. 
27. Hisatoshi Bekki64 et al. proposed that there is accumulating evidence that 
blood pressure control significantly reduces the risk of future cardiovascular 
events in patients with essential hypertension. However, strict BP control is 
often difficult to maintain, and half of hypertensive patients fail to attain BP 
goals on single-drug therapy. Therefore, current guidelines recommend 
combinations of drugs that have complimentary mode of actions for treatment 
of patients with moderate hypertension. In this study, they examined in 
hypertensive patients uncontrolled by the combination treatment with 5 mg 
amlodipine plus 80 mg valsartan or 8 mg candesartan whether additional BP 
lowering could be achieved by switching to 5 mg amlodipine plus 40 mg 
telmisartan. Forty-seven patients with essential hypertension who failed to 
achieve a target BP level by the treatment of 5 mg amlodipine plus 80 mg 
valsartan or 8 mg candesartan for at least 2 months were enrolled. Replacement 
of valsartan or candesartan by telmisartan showed a significant reduction in 
both mean clinic systolic and diastolic BP at 4, 8 and 12 weeks; BP level 
decreased from 143.7/82.3 mmHg at baseline to 135.4/77.5 mmHg at 12 weeks. 
Furthermore, in 8 patients of valsartan group, switching to telmisartan 
significantly reduced central BP by 11.8 mmHg. Our present study suggests 
that combination therapy with telmisartan plus amlodipine may be more 
beneficial than valsartan or candesartan plus amolodipine treatment for 
controlling brachial and central BP, which could lead to more favourable 
cardiovascular outcomes with this drug combination. 
28. Böhm M65 et al. proposed that Clinical trials have shown the efficacy of 
angiotensin II receptor blockers (ARBs) in patients with hypertension and have 
suggested that ARBs are noninferior to angiotensin-converting enzyme (ACE) 
inhibitors in patients with ischemic heart disease and heart failure. The Heart 
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Outcomes Prevention Evaluation (HOPE), a landmark study in high 
cardiovascular risk management, demonstrated the cardioprotection of the ACE 
inhibitor ramipril. Thus, in the recent Ongoing Telmisartan Alone and in 
Combination with Ramipril Global Endpoint Trial (ONTARGET®) ramipril 
was selected as a comparator when exploring the cardioprotective potential of 
telmisartan in the first head-to-head comparison of an ACE inhibitor and an 
ARB in a broad cross-sectional cohort of cardiovascular high-risk patients. 
ONTARGET showed that telmisartan is as effective as ramipril in the 
management of these patients but is better tolerated. The combination of 
ramipril and telmisartan did not confer a further benefit but did bring about an 
increased rate of adverse events such as renal dysfunction. In previous ARB 
outcome trials, cardiovascular risk profile, nature and severity of the underlying 
cardiovascular disease, dosing regimens and concomitant therapies, follow-up, 
and endpoints have varied greatly so that caution is warranted in extrapolating 
evidence gained from high-risk patients to other conditions such as acute 
myocardial infarction or chronic heart failure. 
29. Yusuf S66 et al. studied that Randomized, controlled trials involving about 
150,000 patients have convincingly demonstrated that angiotensin-converting–
enzyme (ACE) inhibitors reduce rates of death, myocardial infarction, stroke, 
and heart failure among patients with heart failure, left ventricular dysfunction, 
previous vascular disease alone, or high-risk diabetes.ACE inhibitors do not 
block the production of all angiotensin II, so direct receptor blockade might be 
more effective. ACE inhibitors reduce bradykinin degradation, which enhances 
vasodilatation, but increase the rates of angioedema and cough. In patients with 
heart failure, angiotensin II levels may increase and symptoms worsen, despite 
the use of ACE inhibitors. The use of an angiotensin-receptor blocker (ARB), 
as compared with placebo, reduced the rate of death or hospitalization for heart 
failure in patients with a low ejection fraction and heart failure who either 
could not tolerate an ACE inhibitor or were already receiving one. As 
compared with beta-blockers, ARBs also reduced vascular events in high-risk 
patients with hypertension and left ventricular hypertrophy. Nevertheless, in 
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other high-risk populations, the role of ARBs as an alternative or in addition to 
ACE inhibitors to prevent cardiovascular outcomes is not known,.They 
evaluated whether the ARB telmisartan was not inferior to the ACE inhibitor 
ramipril and whether a combination of the two drugs was superior to ramipril 
alone as a treatment to prevent vascular events in high-risk patients who had 
cardiovascular disease or diabetes mellitus but did not have heart failure. We 
used a dose of ramipril that had previously been shown to be effective for this 
outcome. 
30. Celik T67 et al. suggested that Prolongation of P-wave times and increase of P-
wave dispersion (PWD) were shown to be independent predictors of atrial 
fibrillation (AF). Angiotensin II receptor blockers (AARBs) and angiotensin-
converting enzyme inhibitors (ACEIs) have beneficial effects on atrial 
conduction times. However, there are not enough data about the comparative 
effects of those drugs on PWD.They aimed to compare the effects of 
telmisartan and ramipril on PWD after 6-month treatment in hypertensive 
patients. Telmisartan has a much greater lowering effect on PWD and 
Pmaximum values than ramipril. This finding may be important in the 
prevention of AF in hypertensive patients. 
31. Zimmermann M68 et al .proposed that Hypertension is one of the most 
important modifiable risk factors for cardiovascular pathology, such as 
atherosclerosis and cardiac left ventricular hypertrophy, including acute events 
such as stroke and myocardial infarction (MI). In particular, the risk of 
ischaemic and haemorrhagic stroke is directly and continuously related to high 
blood pressure levels. The renin-angiotensin system (RAS) plays an important 
role in volume homeostasis and blood pressure regulation. It also helps to 
prevent cell and organ damage from ischaemia during acute volume loss. 
However, angiotensin-II (A-II)the main effector peptide of the RAS also exerts 
a number of pathological effects, which are mediated by the AT 1 receptor. The 
Ongoing Telmisartan  alone and in Combination with Ramipril Global End 
point Trial (ONTARGET) programme consists of two parallel trials where 
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ONTARGET as a large, long-term study compares the efficacy of the 
angiotensin-receptor antagonist, telmisartan, the renin-angiotensin-converting 
enzyme (ACE) inhibitor, ramipril and combination therapy with telmisartan 
plus ramipril for reducing cardiovascular and cerebral risk. Telmisartan, due to 
its long duration of action, compares favourably with other angiotensin-
receptor antagonists. In the Heart Outcomes Prevention Evaluation (HOPE) 
study, ramipril was shown to reduce the risk for MI and other cardiovascular 
events in patients at high risk for pathological cardiac events, but without heart 
failure or a low ejection fraction. The cardiovascular outcomes of high-risk 
patients using the same criteria as those of the HOPE study will be assessed in 
both trials. TRANSCEND differs from ONTARGET in that this trial will enrol 
patients who do not tolerate ACE inhibitors. This parallel study will therefore 
be able to compare telmisartan and placebo treatment. Both ONTARGET and 
TRANSCEND trials feature the same primary composite end point: death 
caused by cardiovascular disease, acute MI, stroke and hospitalisation because 
of congestive heart failure. The secondary end points will focus on reductions 
in the development of Type 2 diabetes mellitus, nephropathy, cognitive 
decrease and dementia as well as atrial fibrillation. 
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AIM AND OBJECTIVES 
 
AIM:           
The aim is to compare inflammatory mediated response and antihypertensive 
efficacy of ramipril and telmisartan in acute coronary syndrome patients.  
 
OBJECTIVES: 
¾ To asses inflammatory mediated response of ramipril and telmisartan by 
comparing high sensitivity c-reactive protein (hs-CRP) levels. 
¾ To find out clinical efficacy of ramipril and telmisartan in lowering of  
the blood pressure. 
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                                        METHODOLOGY 
 
Design of study 
  Randomized, Prospective study. 
 
Location of the study 
This study was carried out in the department  of cardiology of Meenakshi 
Mission Hospital and Research center, Madurai . 
 
Duration of the study  
             Duration of the study-8 months (June 2011-february2012). 
 
Sample size 
90 Patients were entrolled in the study. Among these 43 patients are taking 
ramipril 5mg/OD and 47 patients  are taking telmisartan 40mg/OD. 
 
Inclusion criteria          
          1 .Male or female patients between the age 20-80 years. 
          2.  Patients with clinical evidence of acute coronary syndrome. 
            3.  Patients having BP above 140/90 mm/hg at initial treatment. 
 
Exclusion criteria 
1. Patients with congestive heart failure. 
2. Patients having left ventricular dysfunction. 
3. Patients having MI or stroke ≤3 weeks before study. 
4. Patients with upper respiratory tract infections and acute illness. 
5. Patients with acute infection and trauma. 
6. Patients with clinically apparent inflammatory conditions such as 
rheumatoid arthritis or lupus. 
7. Patients with Blood pressure less than 140/90 mm/hg at initial treatment. 
8. Secondary hypertension or malignant hypertension. 
9. Patients known to be hypersensitive to ramipril or telmisartan. 
10. Patients having history of serious adverse drug reactions to ACE inhibitors 
or angiotensin receptor blockers. 
11. Patients with renal dysfunction. 
Methodology 
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12. Patients receiving combination therapy. 
13. Patients receiving any other investigational drug. 
14. Patients with irregular follow up. 
 
Monitoring parameters 
A. Blood pressure. 
B. High sensitivity c-reactive protein (hs-CRP). 
 
Work strategy 
               Acute coronary syndrome patients with hypertension were enrolled for this 
study. Totally 90 patients were categorized into 2 groups (Group A, Group B). Group 
A (43 patients) are receiving Ramipril 5mg/day and Group B (47patients) are 
receiving Telmisartan 40mg/ day. Clinical evaluation regarding age,gender,social 
habits and evaluation of complications like dyslipidemia , diabetes mellitus were done 
in each case. 
 
             Before treatment with ramipril or telmisartan  hs-CRP (HIgh sensitivity c- 
reactive protein ) test was done. After 90 days of treatment again hs-crp test  was done 
to evaluate inflammatory mediated response. Blood pressure were monitored at 4th,8th 
and 12th week of treatment. BP was monitored for 2 times at 10 minutes interval to get 
correct measurement of BP. The observed parameters are finally evaluated to compare 
the efficacy of one drug over other. 
 
Statistical Tools  
The information collected regarding all the selected cases were recorded 
in a master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship.  
    Observations & Results 
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            OBSERVATIONS AND RESULTS 
           Group A : Ramipril (43 cases) & Group B: Telmisartan (47 cases) 
AGE GROUP DISTRIBUTION: 
                      TABLE NO 1 : AGE GROUP DISTRIBUTION 
 
Age group 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Number of 
patients 
Percentage Number of 
patients 
Percentage
Less than 40 years 8 18.6 6 12.8 
40-49 years 14 32.6 11 23.4 
50-59 years 14 32.6 16 34.0 
60 and above 7 16.3 14 29.8 
Total 43 100 47 100 
Range 32-77 years 33-79 years 
Mean 50.7 years 54.3 years 
SD 12.2 years 12.0 years 
‘p’ value 0.1381  
Not significant 
 
                    When statistical analysis was done ,P value obtained was 0.1381.So there 
was no statistically significant difference observed in age distribution between two 
study groups 
                                  FIG NO 1 : AGE GROUP DISTRIBUTION 
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 SEX DISTRIBUTION: 
                                  TABLE NO 2 : SEX DISTRIBUTION 
Sex Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Number 
of patients
Percentage Number of 
patients 
Percentage 
Male 27 62.8 30 63.8 
Female 16 37.2 17 36.2 
Total 43 100 47 100 
‘p’ value 0.907  
Not significant 
 
When statistical analysis was done ,P value obtained was 0.907. So 
statistically significant difference was not observed in sex distribution between two 
study groups 
                                   FIG NO 2 : SEX DISTRIBUTION 
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        FAMILY HISTORY OF HYPERTENSION: 
              TABLE NO 3 : FAMILY HISTORY OF HYPERTENSION 
 
Family 
History of 
hypertension 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Number  of 
patients 
Percentage Number of 
patients 
Percentage 
Yes 13 30.2 21 44.7 
No 30 69.8 26 55.3 
‘p’ value 0.2323  
Not significant 
 
Statistically significant difference was not observed  in family history of 
hypertension in both  study  groups since P value obtained was 0.2323. 
 
                  FIG NO 3 : FAMILY HISTORY OF HYPERTENSION 
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FAMILY HISTORY OF DIABETES: 
 TABLE NO 4 : FAMILY HISTORY OF DIABETES 
 
Family History of 
diabetes 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Number of 
patients 
Percentage Number of 
patients 
Percentage
Yes 26 60.5 29 61.7 
No 17 39.5 18 38.1 
‘p’ value 0.9334  
Not significant 
 
Statistically  significant difference  was not observed  in family history of 
diabetes among two treatment groups since P value obtained was 0.9334. 
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FAMILY HISTORY OF DYSLIPIDEMIA: 
                    TABLE NO 5 : FAMILY HISTORY OF DYSLIPIDEMIA 
 
Family History of 
dyslipidemia 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Number of 
patients 
Percentage Number of 
patients 
Percentage
Yes 29 67.4 32 68.1 
No 14 32.6 15 31.9 
‘p’ value 0.8724  
Not significant 
  
Statistically significant difference was not observed in  family history of 
dyslipidemia  among  both study groups  since P value obtained was 0.8724. 
 
                 FIG NO 5 : FAMILY HISTORY OF DYSLIPIDEMIA 
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SOCIAL HABITS OF MALE PATIENTS: 
           TABLE NO 6 : SOCIAL HABITS OF MALE PATIENTS  
Social habits Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Number of 
patients 
Percentage Number of 
patients  
Percentage 
Smoker 11 40.7 9 30 0.5584 
Not significant
Alcohol 2 7.4 5 16.7 0.2576  
Not significant
Smoker + 
alcoholic 
8 29.6 9 30 0.7953 
Not significant
Non smoker  
& Non 
Alcoholic 
6 22.2 7 23.3 0.8288 
Not significant
 
 
Statistically  significant  difference  was not observed  in social habits of 
male patients among two study groups  since P values obtained are >0.05 . 
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MEDICAL HISTORY OF DIABETES AND DYSLIPIDEMIA: 
TABLE NO 7  : MEDICAL HISTORY OF DIABETES AND DYSLIPIDEMIA 
Medical 
history 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Number of 
patients 
Percentage Number of 
patients  
Percentage 
Diabetes 7 16.3 10 21.3 0.7373 
Not significant 
Dyslipidemia 17 39.5 11 23.4 0.1549 
Not significant 
Diabetes + 
dyslipidemia 
19 44.2 26 55.3 0.3986 
Not significant 
 
Statistically  significant difference  was not observed in  medical history 
of diabetes and dyslipidemia  among  two study groups since P values obtained 
are > 0.05 .  
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TABLE NO 8 : hs–CRP LEVEL OF PATIENTS BEFORE AND AFTER  
                               TREATMENT 
hS–CRP  
(mg/L) 
GROUP A   
         (Ramipril) 
GROUP B 
(Telmisartan) 
‘p’ 
value 
Mean SD Mean SD 
Before treatment 16.7 4.7 17.3 4.4 0.4476 
Not significant 
After treatment 
(After 90 days) 
4.9 0.7 1.6 0.8 0.0001 
Significant 
 
Statistically  significant difference was observed  in  hs-CRP level of 
patients after treatment  with both groups since P value obtained was 0.0001. 
FIG NO 8 : hs–CRP LEVEL OF PATIENTS BEFORE AND AFTER  
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TABLE NO 9 : CHANGES  IN  hs-CRP LEVEL AFTER TREATMENT  
hS – CRP  
(mg/L) 
GROUP A 
 (Ramipril) 
GROUP B 
(Telmisartan) 
‘p’ 
value 
Mean SD Mean SD  
Change in 90 days 11.8 4.1 15.8 3.7 0.0001 
Significant 
% of change in  
90 days 
69.2 5.5 91.5 3.0 0.0001 
Significant 
 
Statistically  significant difference  was observed  in  change in hs-CRP 
level of patients after treatment  with both groups since P values  obtained  are 
< 0.05 . 
 
FIG NO 9 : PERCENTAGE CHANGES IN hs-CRP LEVEL AFTER                                            
                                        TREATMENT 
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TABLE 10 : SYSTOLIC BP OF PATIENTS DURING VISIT 1  
(Before treatment) 
Systolic BP 
(mm/hg) 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit (1) 
(Before treatment) 
161.6 10.3 159.8 10.2 0.4076 
Not significant
 
Statistically  significant difference was not observed  with  systolic BP 
of patients before treatment with both groups since P value obtained was 
0.4076 . 
  
FIG  10 : SYSTOLIC BP OF PATIENTS DURING VISIT 1 
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TABLE 
             TABLE:11 SYSTOLIC BP OF PATIENTS DURING VISIT 2     (4th 
week) (4THWEEK) 
Systolic BP 
(mm/hg) 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 2 
(4th week) 
146.2 7.9 144.8 9.0 0.3529 
Not significant 
Changes at visit 
2 (4th week) 
15.4 6.3 15.0 6.1 0.98 
Not significant 
% of changes at 
visit 2 
(4th week) 
9.4 3.5 9.3 3.5 0.7029 
Not significant 
 
Statistically  significant difference  was not observed  in systolic BP of 
patients after  treatment  with both groups for 4 weeks, since P values obtained 
were > 0.05. 
FIG 11 : PERCENTAGE CHANGES IN SYSTOLIC BP OF PATIENTS  
DURING VISIT 2 (4TH WEEK) 
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TABLE 12 : SYSTOLIC BP OF PATIENTS DURING VISIT 3 
                                    (8TH WEEK) 
Systolic BP 
(mm/hg) 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 3  
(8th week) 
137.7 7.2 130.9 9.7 0.0014 
Significant 
Changes at visit 3 
(8th week) 
23.9 9.3 28.9 11.9 0.0278 
Significant 
% of changes at 
visit 3 (8th week) 
14.6 5.0 17.9 6.8 0.0088 
Significant 
 
Statistically  significant  difference  was observed with systolic BP of 
patients after treatment with both groups for 8 weeks , since P values obtained 
were < 0.05. 
FIG 12 : PERCENTAGE CHANGES IN SYSTOLIC  BP OF PATIENTS  
DURING VISIT 3 (8TH WEEK)
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TABLE 13 : SYSTOLIC BP OF PATIENTS DURING VISIT (4) 
(12THWEEK) 
Systolic BP 
(mm/hg) 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 4 
(12th week) 
130.5 6.9 116.4 8.2 0.0001 
Significant 
Changes at visit 4 
(12th week) 
31.1 9.6 43.4 13.7 0.0001 
Significant 
% of changes at 
Visit 4 
(12th week) 
19.1 5.0 26.8 7.2 0.0001 
Significant 
 
Statistically significant difference was observed  in systolic BP of patients after 
treatment with both groups for 12  weeks , since P values obtained were <0.05. 
FIG 13 : PERCENTAGE CHANGES IN  SYSTOLIC BP OF PATIENTS 
DURING VISIT (4) (12TH WEEK) 
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TABLE 14 : DIASTOLIC BP OF PATIENTS DURING VISIT 1 
 (BEFORE TREATMENT) 
Diastolic BP 
(mm/hg) 
 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 1 
(Before 
treatment) 
94.7 6.5 96.6 6.2 0.3369 
Not significant 
 
Statistically  significant difference  was not observed  in diastolic BP of 
patients before treatment with both groups since P value obtained was 0.3369. 
 
FIG 14 : DIASTOLIC BP OF PATIENTS DURING VISIT 1( BEFORE TREATMENT) 
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TABLE 15: DIASTOLIC BP OF PATIENTS DURING VISIT 2 (4TH WEEK) 
Diastolic BP 
(mm/hg) 
 
Group A  
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 2  
(4th week) 
88.1 6.3 90.3 6.5 0.0872 
Not significant 
Changes at visit 
2 
(4th week) 
6.5 4.6 6.3 5.2 0.4611 
Not significant 
% of changes at 
visit 3 (8th week) 
6.8 4.8 6.4 5.2 0.366 
Not significant 
 
Statistically  significant difference  was not observed  in diastolic BP of 
patients after  treatment for 4 weeks with both groups, since P values obtained 
were > 0.05. 
FIG 15: PERCENTAGE CHANGES  IN DIASTOLIC BP OF PATIENTS  
DURING  VISIT 2 (4TH WEEK)
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TABLE 16 : DIASTOLIC BP OF PATIENTS DURING VISIT 3 (8TH WEEK) 
Diastolic BP 
(mm/hg) 
 
Group A  
          (Ramipril) 
 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 3  
(8th week) 
87.0 6.4 82.3 6.0 0.0015  
Significant 
Changes at visit 3 
(8th week) 
7.7 5.9 14.3 8.0 0.0001 
Significant 
% of changes at 
visit 3 (8th week) 
7.9 6.0 14.5 7.6 0.0001 
Significant 
 
Statistically significant difference  was observed  in diastolic BP of 
patients after  treatment for 8 weeks with both groups, since P values obtained 
were< 0.05. 
FIG 16 : PERCENTAGE CHANGES  IN DIASTOLIC BP OF PATIENTS                
DURING  VISIT 3 (8TH WEEK) 
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TABLE 17 : DIASTOLIC BP OF PATIENTS DURING VISIT 4 (12TH WEEK) 
Diastolic BP 
(mm/ hg ) 
 
Group A  
             (Ramipril) 
 
Group B 
(Telmisartan) 
‘p’ 
Value 
Mean S.D. Mean S.D. 
Visit 4 
(12th week) 
83.5 5.3 80.2 6.1 0.0106 
Significant 
Changes at visit 4 
(12th week) 
11.2 7.0 16.4 8.1 0.0026 
Significant 
% of changes at 
Visit 4 
(12th week) 
11.5 6.9 16.7 7.5 0.0011 
Significant 
 
     Statistically significant difference  was observed with diastolic BP of 
patients after treatment for 12 weeks with both groups,since P values obtained 
were< 0.05. 
FIG 17 :PERCENTAGE CHANGES  IN  DIASTOLIC BP OF PATIENTS                                  
                                   DURING VISIT 4   (12TH WEEK) 
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TABLE 18 : AGE AND PERCENTAGE OF CHANGES IN SYSTOLIC BP 
Age group Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Mean SD Mean SD 
< 60 years 18.1 4.4 25.3 7.2 
> 60 years 23.7 5.6 30.4 6.1 
‘p’ value 0.0254 
Significant 
0.032 
Significant 
 
In age and percentage changes in systolic blood pressure, P values  obtained 
with group A  and group B are  < 0.05. So statistically significant difference  was 
obsersved between two treatment groups. 
 
FIG 18 : AGE AND PERCENTAGE OF CHANGES IN SYSTOLIC  BP 
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TABLE 19 : SEX AND PERCENTAGE OF CHANGES IN SYSTOLIC BP 
Sex Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Mean SD Mean SD 
Male 20.3 5.0 29.5 6.0 
Female 17.0 4.4 22.1 6.8 
‘p’ value 0.0485 
Significant 
0.0013 
Significant 
 
In sex and percentage  changes  in systolic BP ,P values obtained with 
group A and group B are <0.05.So statistically  significant difference  was 
observed  between   two treatment groups. 
FIG 19 : SEX AND PERCENTAGE OF CHANGES  IN SYSTOLIC BP 
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TABLE 20 : AGE AND PERCENTAGE OF CHANGES  IN DIASTOLIC BP 
Age group Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Mean SD Mean SD 
< 60 years 10.7 6.5 12.4 7.1 
> 60 years 15.7 7.9 17.4 8.6 
 ‘p’ value 0.0408 
Significant 
0.037 
Significant 
 
In age and percentage changes  in diastolic blood pressure, P values 
obtained with  both groups are < 0.05. So statistically  significant difference  
was observed between  both  treatment groups.  
FIG 20 : AGE AND PERCENTAGE OF CHANGES  IN DIASTOLIC BP
10.7
15.7
12.4
17.4
0
4
8
12
16
20
%
 o
f c
ha
ng
es
 in
 D
B
P
 RAMIPRIL
GROUP
TELMISARTAN
GROUP
< 60 yrs > 60 yrs
    Observations & Results 
 
83 
Dept. of Pharmacy Practice, K.M. College of Pharmacy,  Madurai  
 
TABLE 21 : SEX AND PERCENTAGE OF CHANGES IN DIASTOLIC BP 
 
Sex Group A  
(Ramipril) 
Group B 
(Telmisartan) 
Mean SD Mean SD 
Male 12.8 7.4 19.0 7.1 
Female 9.3 5.5 12.7 6.5 
‘p’ value 0.0431 
Significant 
0.0029 
Significant 
 
In sex and percentage  changes in diastolic blood pressure, P values obtained 
with both groups are < 0.05. So statistically  significant difference  was observed 
between both treatment groups.  
 
FIG 21 : SEX AND PERCENTAGE OF CHANGES IN DIASTOLIC BP 
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                      TABLE 22:OVERALL CHANGES IN SYSTOLIC BP 
 
SYSTOLIC BP  
(mm/hg) 
Group A 
(Ramipril) 
Group B 
(Telmisartan) 
‘p’ 
value 
Mean SD Mean SD 
Baseline 161.6 10.3 159.8 10.2 0.4076 
Not significant 
4th week 146.2 7.9 144.8 9.0 0.3529 
Not significant 
8th week 137.7 7.2 130.9 9.7 0.0014 
Significant 
12th week  130.5 6.9 116.4 8.2 0.0001 
Significant 
Change in 12 
weeks 
31.1 9.6 43.4 13.4 0.0001 
Significant 
% of change in  
12 weeks 
19.1 5.0 26.8 7.2 0.0001 
Significant 
 
Statistically significant difference was not observed with systolic BP of 
patients at 4th week since P value obtained was 0.3529.  Statistically significant 
difference was  observed with systolic BP of patients at  8th week since P value 
obtained was 0.0014 . Statistically significant difference was  observed with 
systolic BP of patients at 12th week since P value obtained was 0.0001. P value 
obtained for changes of systolic BP in 12 weeks is 0.0001, so it was  
statistically significant. P value obtained  for percentage of change in 12 weeks 
was 0.0001, so it was statistically significant.  
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                           FIG 22: OVERALL CHANGES IN SYSTOLIC BP 
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               TABLE 23:OVERALL  CHANGES IN DIASTOLIC BP 
DIASTOLIC BP  
(mm/hg) 
GROUPA (Ramipril) GROUP B 
(Telmisartan) 
‘p’ 
value 
Mean SD Mean SD 
Baseline 94.7 6.5 96.6 6.2 0.3369 
Not significant 
4th week 88.1 6.3 90.3 6.5 0.0872 
Not significant 
8th week 87.0 6.4 82.3 6.0 0.0015 
Significant 
12th week  83.5 5.3 80.2 6.1 0.0106 
Significant 
Change in 12 weeks 11.2 7.0 16.4 8.1 0.0026 
Significant 
% of change in  
12 weeks 
11.5 6.9 16.7 7.5 0.0011 
Significant 
 
Statistically significant difference was not observed with diastolic BP of 
patients at 4th week since P value obtained was 0.3369.  Statistically significant 
difference was observed with diastolic BP of patients at 8thweek since P value 
obtained was 0.0015. Statistically significant difference was observed with 
systolic BP of patients at 12th week since P value obtained was 0.0106. P value 
obtained for changes of systolic BP in 12 weeks is 0.0026, so it was  
statistically  significant. P value obtained for percentage of change in 12 weeks 
was 0.0011, so it was statistically significant.  
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                        FIG 23: OVERALL CHANGES IN DIASTOLIC BP 
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                                                       DISCUSSION 
This Study was designed to compare the inflammatory mediated response and  
antihypertensive efficacy of ramipril and telmisartan in acute coronary syndrome 
patients. In the two treatment groups ramipril 5mg/day is compared with telmisartan 
40mg/day. This was a randomized prospective study done to evaluate anti-
inflammatory effect by comparing high sensitivity c- reactive protein levels in acute 
coronary syndrome patients. Antihypertensive efficacy was evaluated by comparing 
regression of blood pressure among the two treatment groups. 
 
In  age group distribution, 43 cases were included in the ramipril group with 
age ranging from 32-77 years,their mean age was 50.7 years .In the telmisartan group 
47 cases were included in the range of 33-79 years, they had a mean age of 54.3 years 
(Table 1).  
 
Generally blood pressure often increases in stages. A person in their 30s may 
have some elevated readings that return to normal. As this person ages, the readings 
increase. If a person develops high blood pressure before the age of 50, his or her risk 
of heart attack or stroke is greatly increased. If untreated, high blood pressure can 
reduce duration of life  by 10 or more years. Men often develop high blood pressure 
between the ages of 35 and 55.Women often develop high blood pressure after 
menopause. Increased age may often associated with a significant increase in the 
prevalence of hypertension and especially of systolic hypertension after age 60 years. 
Increased obesity between age of 30-50 years is associated with significant increases 
in diastolic blood pressure. Increased age is associated with an increased prevalence 
of secondary forms of hypertension including atherosclerotic renovascular 
hypertension, renal insufficiency and primary hypothyroidism. In this study there was 
no statistically significant difference observed between age and study groups. 
 
In sex distribution, ramipril group contains 27 male patients and 16 female 
patients.Telmisartan group contains 30 male patients and 17 female patients. In this 
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study no significant difference was observed in the sex distribution between the two 
study groups (Table 2) . 
Generally male patients may be more hypertensive when compared to females 
due to genetic factors, social habits ,stress and food habits. Hypertension is a major 
risk factor for stroke and cardiovascular disease. In all ethnic groups, men have higher 
mean systolic and diastolic blood pressure compared with women and middle age 
hypertension is more prevalent in men compared with women. Men are less aware 
and receive less treatment for hypertension compared with women. The NHANES III 
survey documented that only 19% of men had their blood pressure controlled. Death 
rates are higher in hypertensive men compared with women, and men are at greater 
risk for stroke, coronary heart disease, heart failure, and renal failure 69. Coronary 
artery disease develops at significantly younger ages in men, thus risk factor 
modification and treatment should begin early in life. Men are at greater risk for 
sleep-related disorders that may contribute to the pathogenesis of hypertension. It is 
important to diagnose such disorders because effective treatment may improve blood 
pressure control. In this study there was no statistically significant difference  
observed between  sex and study groups.  
 
  In family history of hypertension, Out of 43 patients treated with ramipril, 13 
cases (30.2%) have the family history of hypertension. In the case of 30(69.8%) 
patients hypertension have no relation with the family history.  In the case of 
telmisartan group 21(44.7%) cases have family history of hypertension and 26(55.3%) 
cases  doesn’t have family history of hypertension (Table 3).  
 
Generally patients with family history of hypertension may have more chances 
to be hypertensive. Family history of blood pressure is a risk factor for developing 
high blood pressure. Having one or more close family members with high blood 
pressure before the age of 60 means have two times the risk of having it also.  A 
strong family history means patient has 3 or more relatives who had high blood 
pressure before 60.  It is important to understand that a family history of high blood 
pressure does not mean patient will have high blood pressure, but it does increase 
chances. A family history of high blood pressure has been linked to other risk factors 
for heart disease and stroke.  These factors include high cholesterol, high body fat, 
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and being more sensitive to the effects of salt on raising blood pressure. These risk 
factors can put patient at risk for future heart disease and stroke. For persons with 
positive family history, nutritional-hygienic recommendations to avoid overweight 
may be important in reducing the risk of becoming hypertensive. In this study  there 
was no significant difference observed  between two treatment groups.  
 
In family history of diabetes , Out of 43 patients treated with ramipril , 26 
patients (60.5%) have family history of diabetes and 17 patients (39.5%) doesn’t have 
family history of diabetes. In telmisartan group 29 (61.7%) patients have family 
history of diabetes and 18 patients (38.1%)  doesn’t have family history of diabetes 
(Table 4).  
 
Patients with family history of diabetes are more likely to be diabetic. Both 
essential hypertension and diabetes mellitus affect the same major target organs. Left 
ventricular hypertrophy and coronary artery disease are much more common in 
diabetic hypertensive patients than in patients suffering from hypertension or diabetes 
alone. The combined presence of hypertension and diabetes concomitantly accelerates 
the decrease in renal function, the development of diabetic retinopathy and the 
development of cerebral diseases. Lowering blood pressure to less than 130/80 mm/hg 
is the primary goal in the management of the hypertensive diabetic patients. Beta-
blockers have been reported to adversely affect the overall risk factor profile in the 
diabetic patient. In contrast, calcium antagonists, angiotensin-converting enzyme 
inhibitors and angiotensin receptor blockers have been reported to be either neutral or 
beneficial with regard to the overall metabolic risk factor profile. Combination 
therapy is usually required to achieve blood pressure goal in diabetic patients. The 
addition of aldosterone antagonists may be beneficial in patients with resistant 
hypertension and low levels of serum potassium. Aggressive control of blood 
pressure, cholesterol and glucose levels should be attempted to reduce the 
cardiovascular risk of diabetic hypertensive patients. In general, only 25 percent of 
patients with hypertension have adequate control of their blood pressure. Blood 
pressure goals are lower, and thus more difficult to achieve, in patients who also have 
diabetes. Elevated blood pressure is known to contribute to diabetic micro vascular 
and macro vascular complications . Fortunately, reductions in blood pressure can 
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decrease the risk of these complications. In this study no significant difference was 
observed among two treatment groups. 
In family history of dyslipidemia, Out of 43 patients treated with ramipril , 29 
(67.4%) patients  have family  history of dyslipidemia and 14 (32.6%) patients 
doesn’t have family history of dyslipidemia. In telmisartan group 32 (68.1%) patients 
have family history of dyslipidemia and 15(31.9%) patients doesn’t have family 
history of dyslipidemia (Table 5).  
 
Familial combined hyperlipidemia (FCHL) is most common frequent lipid 
abnormality in humans with a 5 to 10 fold increase of early myocardial infraction. 
Familial combined hyperlipidemia has been proposed as the leading cause of 
dyslipidemia in familial dyslipidemic hypertension. FCHL status and waste 
circumference significantly contribute to systolic blood pressure in female FCHL 
relatives. Visceral adipose tissue strongly contribute to high prevalence of 
dyslipidemic hypertension in FCHL families. In this study no significant difference 
observed among the two study groups. 
 
Out of 27 male  patients in ramipril group,11 patients are smokers , 2 patients 
are alcoholics, 8 patients are smokers and alcoholics and 6 patients are not smokers 
and alcoholics. Out of 30 male patients in telmisartan group , 9 patients are smokers , 
5 patients are alcoholics and  9 patients are smokers and alcoholics and 7 patients are 
not smokers and alcoholics (Table 6).  
 
Prevalence of hypertension may be more in patients with smoking and 
alcoholism.In this study no significant difference was observed between two 
treatment groups in social habits of patients. 
 
Out of 43 patients in ramipril group ,7 patients have medical history of 
diabetes ,17 patients have medical history of dyslipidemia and 19 patients  have both. 
Out of 47 patients in telmisartan group ,10 patients have medical history of diabetes, 
11 patients have medical history of dyslipidemia and 26 patients  have both (Table 7).  
 
Patients with medical history of dyslipidemia and diabetes are more prone to 
be hypertensive. Evidence suggests that hypertension may share a similar 
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pathophysiology with cardiovascular disease (CVD). Thus, dyslipidemia, a strong 
predictor of CVD, may also predict incident hypertension. Dyslipidemia may lead to 
the subsequent development of hypertension. Thus, plasma lipids may be useful in the 
identification of men at risk for hypertension. Cardiovascular disease remains the 
leading cause of morbidity and mortality .Two of the most prevalent and 
asymptomatic risk factors for coronary heart disease (CHD) are hypertension and 
dyslipidemia and they commonly co-exist. The CHD risk in patients with co-morbid 
hypertension and dyslipidemia is greater than the sum of CHD risks for hypertension 
and dyslipidemia when they occur alone. Although there are more treatment options 
available today, achieving control of these diseases is challenging. Previous studies 
have found control rates for hypertension around 25% while control of dyslipidemia is 
around 33%. In this study no significant difference was observed in medical history of 
dyslipedemia and diabetes between the two treatment groups. 
 
CHANGES IN hs-CRP 
In this study mean hs-CRP level  of patients before treatment with both groups 
are 16.7mg/l and 17.3 mg/l respectively (Table 8). 
 
After treatment with ramipril and telmisartan for 90 days mean hs-CRP level 
reduced to 4.9mg/l and 1.6mg/l (Table 8). Change of hs-CRP  levels  in 90 days are 
11.8 and 15.8. Percentage of change of hs-CRP levels in 90 days are 69.2% and 
91.5%  for ramipril  and telmisartan respectively (Table 9).  
 
 hs-CRP levels are reduced in both groups after treatment with ramipril and 
telmisartan for 90 days. Telmisartan showed a more significant reduction in hs-CRP 
level by 91.5% when compared to ramipril which shows a reduction by 69.2%. 
(Table9). 
 
CHANGES IN SYSTOLIC BP  
In this study mean systolic BP of patients before treatment with group A and 
group B  were 161.6 mm/hg and 159.8 mm/hg  respectively (Table 10) and after 4 
weeks treatment mean systolic BP reduces to 146.2 mm/hg and 144.8 mm/hg  
respectively. Changes in systolic BP are 15.4 and 15.0. Percentageof change in 
systolic BP are 9.4% and 9.3% (Table 11). 
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In the 8th week, mean systolic BP reduces to  137.7 mm/hg  and 130.9 mm/hg. 
Changes in systolic BP are 23.9 and 28.9. Percentage of  change in systolic BP are 
14.6% and 17.9% respectively (Table 12). 
 
In the 12th week mean systolic BP  reduces to 130.5 mm/hg  and 116.4 mm/hg. 
Changes in systolic BP are 31.1 and 43.4. Percentage  of change in systolic BP are 
19.1% and 26.85% respectively (Table 13).  
 
In 4th week no significant reduction in systolic BP was observed  between  two 
treatment groups. In 8th week and 12th week systolic BP was reduced after treatment 
with  both  groups. But more significant reduction was observed in 12th week (Table 
11, Table 12,Table 13). 
 
Reduction in systolic BP was greater with telmisartan when compared to 
ramipril.  
 
CHANGES IN DIASTOLIC BP 
In this study mean diastolic BP of patients before treatment with both groups 
are 94.7 mm/hg  and 96.6 mm/hg  respectively (Table 14) . 
 
On treatment with ramipril and telmisartan for 4 weeks mean diastolic BP 
reduces to 88.1mm/hg and 90.3mm/hg respectively. Changes in diastolic BP are 6.5 
and 6.3. Percentage changes of diastolic BP are 6.8% and 6.4% (Table 15). 
 
In the 8th week mean diastolic BP reduces to 87.0 mm/hg and 82.3mm/hg. 
Changes in diastolic BP are 7.7 and 14.3. Percentage changes of diastolic BP are 7.9% 
and 14.5% (Table 16). 
 
In the 12th week mean diastolic BP reduces to 83.5 mm/hg and 80.2mm/hg. 
Changes in diastolic BP are 11.2 and 16.4. Percentage changes of diastolic BP are 
11.5% and 16.7% (Table 17). 
 
In 4th week no significant reduction in diastolic BP was observed between two 
treatment groups. In 8th week  and 12th week diastolic  BP was reduced after treatment 
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with both  groups. But more significant reduction was observed in 12th week (Table 
15, Table 16,Table 17). 
 
Reduction in diastolic BP was greater with telmisartan when compared to 
ramipril . 
 
 OVERALL CHANGES IN BLOOD PRESSURE 
                       After 4 weeks of treatment systolic blood pressure values were 
146.2±7.9 mm/hg versus 144.8±9.0 mm/hg (Table 22) and diastolic blood pressure 
values were 88.1±6.3 mm/hg versus 90.3±6.5 mm/hg (Table 23).  No significant 
reduction in BP was observed between two treatment groups.  
 
                        After 8 weeks of treatment systolic blood pressure values were 
137.7±7.2 mm/hg versus 130.9±9.7 mm/hg (Table 22) and diastolic blood pressure 
values were 87.0±6.4 mm/hg versus 82.3±6.0 mm/hg (Table 23) . Significant 
reduction in BP was observed between two treatment groups. 
 
                        After 12 weeks of treatment systolic blood pressure values were 
130.5±6.9 mm/hg versus 116.4±8.2mm/hg and diastolic blood pressure values were 
83.5 ± 5.3 mm/hg versus 80.2 ± 6.1mm/hg (Table 22, Table 23) . After 12  weeks of 
treatment ,the greater significant reduction in BP was observed  in  telmisartan group 
when compared to ramipril.  
                        
                       Percentage of change in systolic blood pressure in 12 weeks are 
19.1±5.0 versus 26.8±7.2 and diastolic blood pressure are 11.5±6.9 versus 16.7±7.5 
(Table 22, Table 23). Greater significant percentage of reduction in BP was observed 
in telmisartan group when compared to ramipril. 
 
 AGE AND SEX WITH HYPERTENSION           
Approximately 30-40% of all people over 65 have high blood pressure. Blood 
pressure control reduces complications associated with hypertension and improves the 
quality of life among elderly people70. The importance of effective BP control in the 
elderly is heightened by the fact that they represent one of the most rapidly growing 
segments of the population. In the case of elderly patients, the physician will aim to 
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achieve a gradual reduction in blood pressure and on possible side effects71. With only 
slightly elevated blood pressure, older patients should reduce excess weight , alcohol 
consumption and should do appropriate physical activities, A low-sodium (salt) diet 
should be recommended for hypertensive patients. The prevalence significantly 
increased with age in both sexes. About 33% of men and 25% of women aged 45-54 
years may have hypertension. About 73% of men and 64% of women aged ≥75 years 
or older may have hypertension72.  
 
                       Significant differences were not observed in age and sex distribution 
between the two groups in this study (Table 1, Table 2). Percentage changes in both 
systolic and diastolic blood pressure with age and sex have shown significant 
relationship between two treatment groups (Table 18, Table 19, Table 20, Table 21).  
 
          Patients having high blood pressure are more likely to develop coronary 
heart diseases. Intensive control of BP is mandatory to prevent complications 
associated with hypertension. Although combination therapy may be required for 
many high risk patients, the initial use of an effective and well tolerated agent should 
improve patient compliance and reduce number of steps needed to reach BP control. 
Life style modification has been recommended as major guide line through out the 
therapy of hypertension since it can effectively reduce blood pressure. 
 
 
 
 
 
 
Conclusion 
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CONCLUSION 
Telmisartan reduces high sensitivity c reactive protein levels to a greater 
extent when compared to ramipril .This study reveals telmisartan has a more potent 
anti-inflammatory effect than ramipril. Anti-inflammatory properties of ramipril and 
telmisartan may have beneficial cardiovascular effects in addition to their blood 
pressure lowering action. 
In this study, telmisartan was consistently more effective than ramipril in 
reducing both systolic and diastolic blood pressure. Regression of blood pressure in 
acute coronary syndrome patients reduces cardiovascular risk and mortality. 
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Annexure 
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                                    CASE RECORD FORM 
Patient data: 
1.Name:    
                                             
2.Age:     
    
3.Sex   
                 
4.MR no: 
 
5.Address:    
                                  
6.Ph no: 
 
7.Drug used: Ramipril          Telmisartan        
 
8.Family history 
   Hypertension:           Yes/No  
   Dyslipidemia:           Yes/No 
   Diabetes:                   Yes/No 
 
9.Social habits of patients 
    Smoker:                    Yes/No     
    Alcoholic:                  Yes/No     
 
10.Medical history 
     Diabetes:                   Yes/No 
     Dyslipidemia:           Yes/No 
 
 
On starting treatment (1st visit)    2nd visit (4thweek) 
Date:        Date: 
Dose of:       Dose of: 
Parameters:       Parameter: 
BP :           SBP/DBP mm/hg    BP:           SBP/DBP mm/hg 
hs-CRP:     mg/l            
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3rd visit(8th week)      4th visit(12th week) 
Date:        Date: 
Dose of:        Dose of: 
Parameter:       Parameters: 
BP :                   SBP/DBP mm/hg    BP:                  SBP/DBP mm/hg 
                                                                                     hs-CRP:             mg/l   
 
 
Any other details :     
 
 
 
Doctor’s signature 
 
 
 
 
 
 
 
